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Abstract

THERAPEUTIC STRATEGIES AIMED
TO FACILITATE AXONAL REGENERATION AND FUNCTIONAL RECOVERY
FOLLOWING TRAUMATIC SPINAL CORD INJURY
By Woon Chow, B.S., B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctorate of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Major Director: Raymond Colello, D.Phil.
Associate Professor, Anatomy and Neurobiology

Traumatic spinal cord injury (SCI) is a physically debilitating, emotionally
devastating, financially costly, and life-changing condition that afflicts more than
1,000,000 people in the United States alone. Owing to the characteristic neuropathology
and low regenerative capacity of the central nervous system, many victims of SCI are left
permanently paralyzed. Though the tissue damage caused by the initial insult almost
certainly cannot be reversed, intensive research in recent years to elucidate the cellular
and molecular events that follows has provided new grounds for optimism. Accordingly,
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in this dissertation, we present a number of potential treatment strategies aimed to address
some of these pathological sequelae seen post-SCI so as to facilitate the regeneration of
axons and the recovery of physiological functions.
After the initial traumatic insult, a prominent and lasting injury-induced
proliferative response occur and results in the development of a gliotic scar that isolates
the lesion from the surrounding viable tissue. Although this process aids to prevent the
spread of uncontrolled tissue damage, the scar nevertheless acts as a physical barrier to
axonal regeneration. Furthermore, cells within the scar are a major source of axon
growth-inhibitory molecules such as chondroitin sulfate proteoglycans (CSPG) and thus
the scar acts concomitantly as a biochemical barrier. Concurrent to all this, inflammatory
cells infiltrate the lesion and promote cell death through immunologic activation.
Neuronal survival is also threatened from the lack of neurotrophic support caused by
axonal severance. Finally, the pathology culminates in the formation of a fluid-filled
cyst, which represents a gap that further hinders axonal regrowth.
Since regeneration cannot physically occur in the presence of a cavity, we, by
employing electrospinning techniques, generated a biocompatible matrix implant that can
bridge and direct axonal elongation across the fluid-filled cyst. Given the complex array
and scope of pathological sequelae post-SCI, it is generally recognized that a
multifaceted approach is required to successfully treat SCI. In view of this, we presented
novel approaches by which successful tried and true therapeutic strategies are combined
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to generate an enhanced matrix. An enzyme as well as a growth factor was incorporated
into our matrix implants in order to respectively neutralize CSPGs and provide
neurotrophic support. Using in vitro assays, we were able to demonstrate excellent
protein bioactivity after incorporation. In vivo experimentation of these enhanced
matrices is now ongoing. To address the injury-induced proliferative response, which
represents an on-ramp off-ramp obstacle that prevents axonal regeneration onto our
matrix implant, we showed how X-irradiation can be utilized to moderate this response
by killing dividing cells so as to facilitate a more efficient penetration of regrowing axons
into and beyond the gliotic scar. Finally, we demonstrate how a novel pharmacologic
agent FTY720 can be used to attenuate the inflammatory response by preventing
lymphocytic egress from lymphoid tissues.
Collectively, these ideas and experimental results represent novel therapeutic
strategies that can be combined in order to bring about meaningful functional recovery
after SCI.

xiv

Chapter 1
Traumatic Spinal Cord Injury: the Epidemiological,
Anatomical, and Pathological

Dissertation Synopsis
This dissertation investigates potential therapies that are directed at various
therapeutic obstacles after traumatic spinal cord injury (SCI). In Chapter 1, we discuss
what is currently known about SCI, specifically the causes and classifications, pathology
and associated therapeutic challenges. In each of the following chapters, the discussion is
then narrowed on a particular obstacle and a potential therapeutic strategy that addresses
the obstacle. Chapter 2 describes electrospinning and how that can be used to fabricate
biocompatible implantable matrices to bridge the fluid-filled cyst. The electrospinning
discussion is expanded in Chapter 3 when we describe how these matrices can be
supplemented with a neurotrophin and an axon growth-inhibitor neutralizing enzyme.
Chapter 4 describes a preliminary study in which these enhanced matrices were
implanted into a rat model of SCI. Chapter 5 focuses on the injury-induced proliferative
response and the potential of using X-irradiation to moderate this reaction. These studies,
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along with some concluding remarks, are summarized in Chapter 6. In the appendix, we
detail a potential pharmacologic intervention to suppress the inflammatory response.

Introduction
Traumatic injury to the spinal cord results in the severing of axons and cell death,
leading ultimately to the disruption of communication pathways between the brain and
distal targets and resulting in paralysis and loss of sensation. A myriad of complex
cellular and biochemical events follow the initial insult, which often further damages the
cord parenchyma and reduces the permissiveness of the microenvironment to axonal
regeneration. Specifically, inflammatory cells infiltrate the lesion area and release toxic
substrates, driving viable neurons and glia alike into apoptosis. Glial cells at the border
of the lesion epicenter react to the injury by hypertrophying and proliferating to form
scar-like barriers and upregulating their expression of various axon growth-inhibitory
compounds. Concurrently, parenchymal destruction leads to the formation of a fluidfilled cyst, resulting in a physical gap that further complicates the prospect of
regeneration. In short, the cellular and biochemical responses following SCI are
numerous, complex, and possess certain elements of destruction. Thus, potential
treatments for SCI were generally unavailable until the last few decades. And though
little can be done to reverse the initial insult, through our increasing understanding of the
pathology seen after SCI, new potential treatment strategies that target specific
therapeutic obstacles can be devised and combined to bring about meaningful functional
recovery.
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In this introductory chapter, we first present some general information about SCI
including statistics, basic anatomy, and classifications before proceeding to discuss
individually each of the major therapeutic obstacles that confront researchers and
clinicians. Later, in the remaining chapters, we shall describe our ideas and the
investigations of these ideas for addressing each of these obstacles.

Epidemiological Statistics
The prevalence of SCI in the U.S. is often cited by the literature and various
special interest groups to be from a conservative number of 200,000 (Berkowitz, 1998) to
a higher estimation of 450,000 cases (National Spinal Cord Injury Association).
Incidence is estimated to be approximately 11,000 cases each year (Berkowitz, 1998).
However, a recent 2009 report from a project led by researchers at the University of New
Mexico’s Center for Development and Disability suggests that there may be a gross
underestimation of SCI prevalence in this country (Christopher & Dana Reeves
Foundation). The project, which included exhaustive surveys conducted on more than
33,000 randomly sampled households, estimated that there may be an upward of
1,275,000 people, or approximately 0.4%, of the U.S. population, currently living with
SCI. According to this newly generated report, more than 82% of the SCI cases were
caused by trauma, with 28% of the cases resulting from occupational accidents, 24%
from motor vehicle accidents, 16% from sport-related injuries, 9% from falls, 4% from
violence-related injuries, and 1% from natural disaster-related injuries. Paraplegia is
documented in about 43% of SCI cases while quadriplegia in about 56%. Of those

3

reported being paralyzed due to a SCI, 61% were males. Currently, SCI costs the U.S.
health care system approximately $40.5 billion annually, a four-fold increase from the
estimated cost of 9.7 billion in 1998. The considerable annual costs of living with SCI
coupled with the overwhelming physical and emotional hardship suffered by both the
patient and family make SCI an important public health concern that is worthy of finding
a cure.

Spinal Cord Anatomy
Enclosed within and protected by the bony vertebral column in the spinal canal,
the human spinal cord is a long, thin, soft, ovoid-shaped bundle of nervous tissue that
extends inferiorly from the medulla oblongata at the level of the foramen magnum to
typically the upper lumbar vertebral level. Considered to be a part of the central nervous
system (CNS) along with the brain, the spinal cord is similarly ensheathed by the three
meninges, which include the outer dura mater, the arachnoid mater, and the innermost pia
mater. Cerebrospinal fluid is found in the subarachnoid space as in the brain as well as in
the central canal, the adult remnant of the neural tube. The peripherally located white
matter of the spinal cord contains ascending and descending neural tracts of axons that
act as signal transmission conduits between the brain and the rest of the body. Damage to
these tracts in a SCI causes a majority of the symptoms seen post-injury. The centrally
located gray matter contains neuronal cell bodies that are involved with motor control,
reflexive loops, and central pattern generation. Enlargements, which are portions of
increased girth due to the greater amount of tissue needed to innervate the limbs, are
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found at the cervical and lumbar levels. In general across mammalian species, the more
dorsal aspect of the cord contains tissue that are associated with afferent, or sensory,
inputs and the more ventral aspect contains tissue that are associated with efferent, or
motor, outputs.
The anatomy of the spinal cord and its surrounding structures plays a considerable
role in explaining the favored level of injury in SCI. SCI generally occur at the level of
the cervical and lumbar cord, which is attributable to the presence of the enlargements at
these locations. Due to the compact physical space between the cord and the spinal canal
at these vertebral levels, the spinal cord can easily be trapped and compressed if there is
any orthopedic involvement when trauma occurs. In contrast, mid-thoracic cord injuries
are quite rare, since a small but significant space cushion exists between the cord and
bone.

Spinal Cord Injury Pathological and Clinical Classification
Pathological Classification
Spinal cord trauma can be a result of any or the combination of the following:
application of pressure such as stretching or squeezing, bruising, tearing, or crushing.
The manner by which the spinal cord is injured has considerable influence on the
prognosis as well as the therapeutic strategies involved. Accordingly, a pathological
classification, initially devised by Bunge et al. (1993), relates the manner by which the
cord is injured to the gross appearance and histology of the cord seen at autopsies. The
four groups included in this classification are solid cord injuries, contusion/cavitation
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injuries, laceration injuries, and massive compression injuries, with each of these types
corresponding respectively to the manner of injury stated above.

Solid Cord Injuries
Solid cord injuries are SCI in which no gross defects are seen. Grossly, the cord
appears normal, with no softening, bruising, discoloration, or a compromise of the
meninges. However, histologically, sections show a loss of normal architecture,
demonstrating the occurrence of damage (Figure 1.1B). Solid cord injuries are rare and
are only involved in about 10% of SCI cases. The cause of solid cord injuries is still
unclear, though inflammation is thought to play a major role in the development of these
injuries. It is suggested perhaps that a slight application of pressure on the cord, such as
stretching or squeezing, which in itself is relatively harmless to cord tissue, is enough to
trigger an inflammatory cascade. The ensuing inflammation, as an insidious component
of secondary injury, damages spinal cord tissue. (Primary injury is the initial insult.)
Frequently, minor cases of SCI may not initially present with any clinical findings
and only later does the patient begin to exhibit symptoms of a SCI. This very fact
supports the general notion that perhaps much of the tissue damage sustained after a
primary SCI insult, especially in cases where cord anatomy was not drastically altered, is
due to secondary injury. Accordingly, the many notable potential therapeutic strategies
to SCI and traumatic brain injury alike seen in the literature often target a component of
secondary injury.
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Contusion/Cavitation Injuries
The second type, contusion/cavitation injuries, is the most common and is
involved in more than half of all traumatic SCI cases. Also known as percussive SCI,
these injuries are usually caused by a dislocated vertebra or displaced discs and ligaments
compressing and subsequently bruising the cord. Grossly, there is no disruption of the
pial surface despite the fact that often there are areas of hemorrhage in the central grey
matter. These areas eventually undergo liquefactive necrosis and the debris is
subsequently cleared by inflammatory cells, ultimately resulting in the classical
formation of a fluid-filled cyst (Figure 1.1C). Concurrently, a prominent reactive
astrogliotic reaction around the lesion site ultimately develops into a gliotic scar
surrounding the cyst.

Laceration Injuries
The third type, laceration injuries, account for about 20% of SCI cases. Often,
these injuries are a result of broken fragments of vertebra cutting the cord. Gun-shot and
stab wounds are also responsible. In contrast to contusion/cavitation injuries, rupturing in
the pial membrane is apparent (Figure 1.1D). As a consequence, extra-medullary
fibroblasts migrate into the lesion site, deposit a substantial quantity of collagen, and
ultimately form a mesenchymal scar. The prognosis of laceration injuries is often poor
since the dense scarring characteristically blocks any attempts of axonal regrowth or
rewiring. Minor functional improvements can often be seen in SCI patients post-trauma
as the injury stabilizes, but this rarely occurs in laceration SCI.
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Massive Compression Injuries
Finally, in massive compression injuries, the cord is essentially crushed, usually
from extensive orthopedic trauma. The pathological evolution of these lesions is similar
to that of laceration injuries due to the pial disruption. Accordingly, considerable fibrosis
and dural adhesion typically results (Figure 1.1E). Less than a 20% of traumatic SCI
cases are classified as massive compression injuries.
Most SCI cases can be classed as one of these four types. However, some
injuries, especially multi-level ones, may involve more than one of these pathologies.
Outwardly, this pathological categorization scheme seems somewhat overly simplified,
but nevertheless helpful when prognosticating the progression of a SCI.

Clinical Classification
In contrast to the pathological classification, a clinical classification of SCI is
based on the functional implications post-injury. In general, SCI can be classified as
complete, incomplete, or discomplete. Complete injuries usually involve trauma so
severe that there is total paralysis and sensation loss below the level of the lesion. This
clinical type frequently implies a total cord transection, which is an exceptionally
uncommon event. In contrast, incomplete injuries signify that some physiological
function is preserved below the injury level. The implication here is that the cord has not
been completely severed. In many cases of incomplete injury, the cord is generally
anatomically intact but the injury has caused disruption in some but not all the neural
tracts. Finally, discomplete injuries appear to be clinically complete but
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neurophysiologically incomplete. Patients with this type of injury are completely
paralyzed below the lesion, but they exhibit some brain influence on spinal cord function.
This presentation of SCI has not been fully explained and the cause is still unclear.
Generally, once a SCI patient is stable after admission, he or she often undergoes
extensive testing to determine the completeness as well as the physiological level of
injury. This evaluation includes assessing the three major afferent and efferent spinal
cord pathways, specifically the dorsal column tracts with pinpricks and the spinothalamic
tracts with light touches at all dermatomes plus the corticospinal tracts with muscle
strength tests on all major muscle groups.
These classifications convey the varieties and range of clinical and pathological
consequences after SCI. Accordingly, SCI treatment strategies must be tailored to the
specific injury type.

The Obstacles to Successfully Treating Spinal Cord Injury
In this project, we were most interested in furthering our understanding of and
testing improved potential therapies for contusion/cavitation typed SCI since as
aforementioned, they are the most common cases clinically. In the following sections,
the therapeutic obstacles to successfully treating this percussive type of SCI are
discussed. These obstacles, as well as our therapeutic ideas for addressing them, are
revisited in the remaining chapters individually.
In short, percussive injury to the cord in both humans and animal models results
in a pathological cascade of cellular and molecular events that culminate in the
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characteristic formation of a fluid-filled cyst enclosed by a cellular wall made by the
proliferation of glial cells and subsequent scarring (Balentine, 1978; Wozniewicz et al.,
1983; Kakulas, 1984; Bresnahan et al., 1991; Bunge et al., 1993; Ito et al., 1997;
Norenburg et al., 2004). The cyst forms a physical gap within the cord parenchyma,
preventing axons from crossing the lesion to reach downstream targets. The gliotic scar,
formed by the hypertrophy and hyperplasia of various cells in and around the lesion,
presents a physical as well as biochemical barrier due to the increased cellular expression
of compounds that inhibit growth cone migration (Lemons et al., 1999; Morgenstern et
al., 2002). In addition to these pathological hallmarks, inflammation, mentioned
previously as a component of secondary injury, plays an insidious role in the promotion
of cellular apoptosis, exacerbating the damage initially sustained by the primary insult
(Anderson et al., 1985; Blight, 1992). Furthermore, the loss of trophic support
exacerbates neuronal cell death. These SCI pathological features of scar development,
inflammation, cavity formation, molecular inhibitors, and loss of trophic support are now
discussed in greater detail.

Cyst Formation
Though cystic formations generally occur late in the pathologic evolution of the
SCI lesion, we initiate our discussion with this topic since they represent the single most
prominent obstacle to axonal regeneration. Customarily found in contusion/cavitation
injuries, fluid-filled cysts typically form at injury epicenters weeks to months following
SCI (Balentine, 1978; Norenburg et al., 2004). Cysts may have a singular, multiple, or
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multiloculated presentation and a wall of gliotic scarring, deposited during the lesionisolation process, surrounds the cysts. The cysts are essentially the end products of debris
clean-up at the lesion site and they represent the final healed state of a CNS injury.
Similar to cysts in that they are fluid filled, syrinxes, differ in that they possess a thicker
and denser gliotic wall due to increased pressure in the cavity. Syrinxes may exacerbate
existing neurological deficits since adjacent cord parenchyma may be compress as the
cavity increase in size. Cavity formations are yet another obstacle in successfully treating
SCIs. Due to the lack of a solid substrate, this pathological endpoint represents a
physical gap that prevents regenerating axons from crossing to reach their downstream
targets.
To this end, in Chapter 2, we show how electrospinning was utilized to fabricate a
bridging matrix. Recognizing that an ideal bridging scaffold would be biocompatible,
durable, porous, and directional such that it can spatially guide regrowing axons, we
generated via electrospinning a matrix that possess all of these properties and
demonstrated their excellent neurite-guiding ability in vitro. Furthermore, in Chapter 3,
in preparation for the assessment of these matrices in vivo, we show how we refined the
electrospinning process by adopting an air-gap spinning system so as to generate
implantable 3-dimensional cylindrical structures possessing the same qualities that are
capable of filling the gap left within the damaged cord. A preliminary test of these
matrices in an animal model of SCI is presented in Chapter 4.
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Chondroitin Sulfate Proteoglycans
After SCI, glial cells within the scar and in the surrounding lesion zone proliferate
and hypertrophy to form the gliotic scar. In addition, these cells upregulate their
expression of CSPGs (Lemons et al., 1999). CSPGs are well-known inhibitors of axonal
regeneration (McKeon et al., 1995; Canning et al., 1996; Gopalakrishnan et al., 2008;
Yang and Schnaar, 2008).
Chondroitin sulfate is simply a sulfated glycosaminoglycan (GAG), which is a
long unbranched polysaccharide consisting of a variable number of repeating
disaccharide units. One or more of these chains are often found attached to a core protein
via a serine residue as part of a proteoglycan. Depending on the core protein to which the
GAG chain is attached, the entire molecule is called by a distinctive name. Examples of
CSPG molecules include aggecan, brevican, neurocan, phosphacan, versican, and NG2.
The pattern of sulfation can be rather complex as each disaccharide possesses four
possible positions for group attachment and the diseaccharide may be unsulfated or
sulfated in 1, 2, or 3 positions. For this reason, there can be a very large number of
sulfation motifs which defines the individual binding site.
CSPGs are expressed almost ubiquitously and are found in the ECM of most
tissues. In addition to their structural role in the ECM, these molecules are important
regulators in various biological processes involving cellular recognition, migration, and
signaling (Brittis et al., 1992; Sheng et al., 2005). In certain tissues, they provide very
specific functions. For example, CSPGs are a major component of cartilage and by virtue
of their numerous tightly packed and highly negatively charged sulfate groups, generate
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the electrostatic repulsion that provides much of the compression resistance. In the
nervous system, they contribute to the regulation of various CNS developmental
processes, acting as a stop signal to neuronal and axonal growth cone migration (Powell
et al., 1997; Cortes et al., 2009).
Upon injury to the CNS, there is a general massive upregulation of CSPGs at the
lesion site and surrounding areas (Lemons et al., 1999). Although this expression usually
peaks during the first week post-injury, levels of CSPG usually stay high as the gliotic
scar matures (Tang et al., 2003). The production of a certain CSPG is attributable
generally to a particular cell type. Brevican and phosphacan are mainly products of
astrocytes whereas versican and NG2 are almost exclusively expressed by
oligodendrocyte progenitor cells (OPC) (McKeon et al., 1999; Asher et al., 2002;
Bouslama-Oueghlani et al., 2005). Neurocan is produced by both astrocytes and OPCs
(Asher et al., 2000).
The exact mechanism by which CSPGs inhibit the regeneration of axon is still
unclear. Substantial evidence suggests that the sulfated GAG chains are the elements
responsible. Nevertheless, it is well-recognized that successful SCI therapies include an
element that targets these nefarious molecules so as to neutralize their axon growthinhibitory property. In vitro experimentation by various research groups with the
bacterial enzyme chondroitinase ABC (ChABC), which cleaves the GAG chains, have
shown a drastic reduction of the inhibitory activity of CSPGs (Iaci et al., 2007; Massey et
al., 2008). Furthermore, recent in vivo studies using ChABC demonstrated enhanced
axonal sprouting and neuroplasticity as well as improved functional recovery (Bradbury
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et al., 2002; Caggiano et al., 2005; Huang et al., 2006; Tester and Howland, 2007). In
view of these successes by others, in Chpater 3, we show how we integrate ChABC into
our implantable electrospun matrices as well as present data from in vitro assays that
demonstrate the extent to which the enzyme remained bioactive.

Neurotrophins
Neurotrophic factors, or neurotrophins, are small, secreted peptides that act on
cells in the nervous system via specific receptors that activate intracellular signaling
cascades to promote cell survival, growth, and differentiation (Markus et al., 2003). In
general, neurons projecting axons via specific tracts within the spinal cord respond to one
particular neurotrophin or a collection of factors.
The nerve growth factor (NGF) family of neurotrophins includes the four related
peptides that share structural and sequence homology: NGF, brain-derived neurotrophic
factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). These factors can
bind to two entirely distinct classes of receptors. The first known targets, Trk
(tropomyosin receptor kinase) receptors are a family of tyrosine protein kinase receptors
that mediates high affinity binding. Each of the Trk receptor members bind only with
specific neurotrophins. TrkA receptors, which are expressed by sympathetic, trigeminal,
and dorsal root ganglion neurons as well as by cholinergic neurons of the striatum and
basal forebrain, specifically recognize NGF (Barbacid, 2004). TrkB receptors are
activated primarily though their binding with BDNF and NT-4. The principal targets of
NT-3 are TrkC receptors, which have been shown to be expressed on developing
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corticospinal neurons (Chen et al., 1996, Namiki et al., 2000; Iarikov et al., 2007). In
some cellular contexts, NT-3 is also able to bind TrkA and TrkB, though with less
efficiency. Activation of the Trk class of receptors results in the prototypical function of
neurotrophins, namely the promotion of cell survival and growth. The second known
target (though first discovered) of neurotrophins is the p75 neurotrophin receptor
(p75NTR), a member of the tumor necrosis receptor superfamily. In contrast to the Trk
family, all four mentioned neurotrophins are able to bind to p75NTR, although with
much less but similar affinity. The specific role of p75NTR is not entirely clear. Due to
their low affinity for the neurotrophins, some have suggested that p75NTR may act to
take up excess concentrations and affecting neurons in a manner beyond survival and
growth in such occasions. The p75NTR is known to be highly expressed in certain
developing neurons as well as in axotomized adult neurons, which suggests a
physiological role in mediating the higher neurotrophin expression by the local glial cell
population seen after trauma. It has been demonstrated that p75NTR increases both the
binding affinity and specificity for Trk receptor. This is especially evident with NGF in
that both p75NTR and TrkA are required for the efficient generation of high affinity
binding sites (Esposito et al., 2001). However, other studies have point to the role of
p75NTR as a pro-apoptotic mediator. Cells expressing P75NTR in the absence of Trk
receptors may be driven to programmed cell death in the presence of a neurotrophin
rather than surviving (Teng et al., 2005). Another interesting observation related to SCI
is the relationship between the p75NTR and Nogo-66 receptor. The Nogo-66 receptor,
with its downstream Rho kinase pathway, is responsible for mediating the inhibitory
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effects on axonal growth of three notorious myelin-associated glycoproteins, specifically
Nogo-A, myelin-associated glycoprotein and oligodendrocyte-myelin glycoprotein (Liu
et al., 2002; Xie and Zheng, 2008). The p75NTR receptor act as a co-receptor to the
Nogo receptor complex and when p75NTR was knocked out in mice, outgrowth
inhibition of axons was no longer observed (Wang et al., 2002; Wong et al., 2002). In
short, though the meaning of the association between P75NTR and Trk, with some
seemingly synergistic and others antagonistic effects, is still quite controversial, it is
apparent that there are independent and dependent roles and actions of these two types of
receptors.
After ligand binding, the high affinity Trk receptors undergo dimerization and
autophosphorylates tyrosine residues in their cytoplasmic domains. The neurotrophins
and its activated Trk receptors are subsequently internalized through clathrin-coated pits
and conveyed retrogradely up the axon toward the neuronal soma. This endocytosis and
subsequent vesticular transport serves to bring the activated signal close to certain
organelles, such as the nucleus, where the signal can be acted upon to bring about
specific cellular responses by way of gene transcription. Signaling in the neuronal cell
body controls the more global cellular functions of survival, proliferation, and
differientation (Jacobson et al., 1997). In contrast, local signaling is also known to occur
and has been shown to regulate growth cone motility (Thoenen and Barde, 1980). In one
study, Gallo et al. was able to demonstrate that the TrkA receptor mediated growth cone
turning toward a localized source of NGF (1997). The molecular mechanisms by which
neurotrophins regulate growth cone motility are not well understood. However, recently
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acquired experimental evidence suggests that these Trk-dependent actions may converge
downstream with the abovementioned Rho kinase pathway and that a local accumulation
of actin filaments may result from an increase in intracellular calcium concentration
(Gehler et al., 2004).
In general, neurons in the CNS obtain their trophic support from the target tissue
to which their axons project and this secretion of neurotrophins by the target tissue
prevents the associated neuron from initiating apoptosis. Thus, a low maintenance level
of neurotrophins is required to ensure neuronal survival. Upon axotomy after SCI, the
disconnected neurons no longer receive a survival signal and may be driven into
programmed cell death. However, studies have shown that exogenous introduction of
neurotrophins after CNS injury rescues these axotomized neurons, ensuring cell survival
and in many cases cause enhanced axonal regrowth (Namiki et al., 2000; Mitsui et al.,
2005; Blesch and Tuszynski, 2007). Accordingly, also in Chapter 3, we describe the
incorporation of NGF into our implantable electrospun matrices by way of alginate
microspheres and present data from in vitro assays that demonstrate the extent to which
the growth factor remained bioactive when incorporated.

Reactive Astrogliosis and Gliotic Scar Formation
In human percussive SCI, the reactive astrogliotic, or gemistocytic, response is
characterized by cellular hypertrophy and injury-induced proliferation, which ultimately
results in a gliotic scar that is classically seen around the boundary of the lesion epicenter
(Figure 1.2). This outcome brings about a number of neuroprotective benefits. As a new
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glia limitans forms, reactive gliotic processes interdigitate and become linked by tight
junctions. This functions to isolate the SCI lesion containing necrotic tissue debris from
viable tissue in the periphery, resulting in the reestablishment of the integrity of the CNS
microenvironment within and aiding to prevent a further spread of cellular destruction
(Norenburg et al., 2004). Astrocytes within the developing gliotic scar are known to play
a homeostatic role in restoring extracellular ionic balance and uptaking of the excess
excitatory neurotransmitters and other toxic metabolites that may have accumulated in
the lesion and the surrounding cord tissue (Davies et al., 2006; White and Jakeman,
2008). Furthermore, as the gliotic scar forms, reactive astrocytes often extensively
remodel the extracellular matrix (ECM) and lay down abundant deposits of basal
membrane. Analogous to wound contracture after skin injuries, this basal membrane can
contract to bring together opposite margins of the lesion, shrinking the lesion as debris is
cleared out. In addition, the gliotic scar provides a cellular scaffold for inwardly
migrating epithelial cells to revascularize the lesion site.
In contrast to the above benefits, the scar has been implicated in blocking axonal
regeneration physically as well as biochemically via the expression of chondroitin sulfate
proteoglycans (CSPG) and other inhibitory factors. First causally suggested by Ramón y
Cajal (1928), subsequent experimental results readily confirms that though regenerating
CNS axons sprout growth cones, axonal regrowth and growth cone migration invariably
stop at the gliotic scar border (Reier et al., 1986). The cause of the physical barrier is still
unclear. Though the gliotic scar is sealed sufficiently to prevent the spread of damage
peripherally from the lesion epicenter, many studies have shown that astrocytic processes
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and their associated tight junctions do not create a physical impediment (Norenburg et al.,
2004). However, there is a possibility that the basal membrane is capable of obstructing
axonal regrowth due to its contractile properties, resulting in its dense architecture.
Consequently, success in inducing regenerating axons to regrow past the scar to seek
distal targets requires a physical alteration of the scar to some extent.
In view of the inability of regenerating axons to penetrate the scar to reach our
implantable electrospun matrix scaffold and off on the opposite side, in Chapter 5, we
present a potential non-invasive therapy in which single-dose X-irradiation is used to
moderate the injury-induced proliferative response so as to increase the spatial separation
between reactive cells, which may create small gaps to facilitate regeneration at the onramp and off-ramp sites adjacent to the matrix. The attenuation of cellular proliferation
needs not be extreme since gliotic scarring nevertheless confers important
neuroprotective benefits.

Edema and Inflammation
Edema is often the first gross sign following SCI that can be detected, usually
radiographically. This edema is probably due to the vascular changes, namely
vasodilation and hyperemia, which occur early on in the injury response (Sharma et al.,
1993). Specifically, a breakdown of the blood-spinal cord barrier, loss of cerebral
autoregulation, and the consequent increased permeability of capillaries results in an
exudation of plasma fluid into the extracellular space. This vasogenic edema can cause
an ischemia that may possibly be due to the increased hydrostatic pressure in the region.
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In contrast to the brain, the spinal cord has a thicker and perhaps more rigid pial-glial
zone, which can exacerbate this ischemic mechanism. This ischemia can in turn cause a
buildup of undesirable metabolites and excitatory neurotransmitters, causing more
neurons in the vicinity to die (Stiefel et al., 2005). Research completed at this institution
has shown that perhaps more significant than vasogenic edema is the cytotoxic edema
that may be caused by these events (Marmarou et al., 2006). This mostly occurs in
astrocytes, especially those with astrocytic end-feet adjacent to capillaries (Bullock et al.,
1991).
The basis for the increased permeability of the blood-spinal cord barrier is
attributed generally to a host of secreted factors. It is well-established that expressions of
pro-inflammatory cytokines such as Interleukin (IL)-1, IL-3, and IL-6 as well as their
associated receptors are strongly upregulated post-injury. In addition, various
complement components and tumor necrosis factor (TNF) were also observed to be
increased in their expression. These and a number of other factors, such as various
matrix metalloproteinases, may be responsible for the enhancement of vascular
permeability and the subsequent infiltration of immune cells. Furthermore, the sustained
elevations of particularly TNFα and IL-1β may cause neuronal and oligodendroglial cell
death (Lee et al., 2000; Hermann et al., 2001; Cai et al., 2003). Accordingly, blocking
TNFα and IL-1β have shown to be neuroprotective in various models of CNS trauma
(Nesic et al., 2001; Genovese et al., 2006). Though it is recognized that cytokines play
an important and seemingly destructive role in mediating the inflammatory reaction
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following SCI, the full extent of involvement by these various pro-inflammatory factors
on the secondary degenerative processes remains unclear.
As mentioned, the cytokine mediated vascular changes attract inflammatory cells
into the lesion site (Trivedi et al., 2006). As shown in animal studies, compared to posttraumatic inflammation in brain injuries, SCI tends to elicit a more prominent cellular
immune response (Schnell et al., 1999a). Following identical laceration injuries
delivered to mouse brain and spinal cord, higher numbers of neutrophils and activated
macrophages were shown to be recruited to the SCI lesion site and their extent of
infiltration was more profound. In a subsequent study by the same group, similar results
were obtained when non-traumatic injections of pro-inflammatory cytokines into the two
different tissues—neutrophil and macrophage recruitment was always greater in the
spinal cord (Schnell et al., 1999b). Anatomical and molecular variabilities between the
brain and spinal cord may account for these regional differences in inflammatory
reactions (Tveten, 1976a, b). Nevertheless, these results demonstrate that knowledge and
data gleaned from studying CNS inflammation in the brain cannot be applied to SCI
without further examination.
After injury to the cord parenchyma, blood monocytes, granulocytes, and
lymphocytes readily migrate across the permeable blood-spinal cord barrier. It has been
demonstrated numerous times that immune cell infiltration into the SCI lesion site largely
contributes to the secondary injury process and may considerably expands lesion volume
(Dusart and Schwab, 1994; Blight et al., 1995; Glaser et al., 2004). The earliest arrival of
neutrophils usually occurs within 12 h with ED1 immunoreactive macrophages appearing
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soon after (Carlson et al., 1998; Norenburg et al., 2004). These cells phagocytose cellular
and myelin debris and begin the intensive clean-up process that may continue for the next
3 to 5 d. By day 3, numerous fat-laden macrophages occupy the lesion site. Though the
process of debris removal in itself is beneficial, many researchers have suggested that a
number of elements may perhaps be neurotoxic. Neutrophils release a potent cocktail of
reactive oxygen species and enzymes intended for a bacterial invasion. It is almost
certain that neutrophils confer no meaningful neuroprotection in the CNS post-injury
given their foremost function as bactericidal cells.
Lymphocytes, in particular the T cell, have been implicated in promoting cellular
apoptosis following the release of neural self-antigens and the resulting activation of
immunological cascades after CNS injury (Popovich et al., 1996; Gonzalez et al., 2003;
Ankeny et al., 2006). In experimental trials, injection of activated T cells from SCI rats
alone has shown to cause CNS injury in naïve animals (Popovich et al., 1996).
Consequently, one element of a successful SCI therapy must include a means to modulate
the inflammatory response so as to reduce cell death and preserve the enduring viable
tissue parenchyma surrounding the lesion site.
Accordingly, in the appendix, we present a potential pharmacologic therapy that
aims to induce lymphopenia following SCI. By preventing lymphocytic egress from
lymph nodes, we show the extent to which fingolimod, commonly known as FTY720,
preserves cord white matter, improves bladder function, and enhances functional
recovery.
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Summary
Figure 1.3 illustrates and summarizes the major therapeutic challenges posed by
SCI that we have just now discussed. Given the multitude and the variety of obstacles,
SCI is a costly, debilitating, and life-changing medical condition that will require a
combination of approaches to successfully treat. In the following chapters, we will
present our ideas and the investigations of these ideas for addressing each of these key
challenges.

23

24

Figure 1.1. (A) Cross sectional histology of a normal human spinal cord at the cervical
level. (B) Cords in solid cord injuries display a loss of the normal tissue architecture.
(C) Cystic formation in cord parenchyma in contusion/cavitation injuries. (D) Pia is
penetrated in laceration injuries. (E) Massive compression injuries generally results in
the pulpification of cord tissue and extensive hemorrhage. Scale Bars (A to E) = 2 mm.
Adapted from Norenberg et al. (2004).
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Figure 1.2. (A) Longitudinal sections of a rat spinal cord, which received a contusion
injury 14 d earlier, immunolabeled for GFAP (red). Gliotic scarring is readily seen by
the high intensity of labeling around the edge of the developing cyst located at the lesion
epicenter. (B) The same section immunolabeled for bromodeoxyuridine (green), a
proliferation marker. Scale Bars (A and B) = 1 mm.
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Figure 1.3. A cartoon illustrating the various therapeutic challenges posed by
contusion/cavitation SCI. Adapted from Fitch and Silver (2008).
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Chapter 2
Evaluating Neuronal and Glial Growth on Electrospun
Polarized Matrices

Introduction
Percussive injury to the spinal cord, in both human insults and animal models,
results in the liquefactive necrosis of the tissue in and around the lesion site. Commonly,
a fluid-filled cyst is the final consequence of this process. Because of the lack of a solid
substrate, this late-stage pathological endpoint presents a physical gap which impedes
axonal regeneration and functional recovery after spinal cord injury (SCI). Though other
therapeutic obstacles exist post-SCI, the cystic formation represents a single most
formidable challenge to axonal regrowth.
To guide regenerating axons across this cavity, several research groups have
investigated the use of bridging materials that include substrates derived from either stem
cells (McDonald et al., 1999; Akiyama et al., 2002), support cells (Xu et al., 1995; Li et
al., 1997), autologous grafts (von Wild and Brunelli, 2003; Houle et al., 2006),
embryonic grafts (Reier et al., 1986), natural substances (Marchand et al., 1993), or
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synthetic substances (Tsai et al., 2004; Wen and Tresco, 2006). Many of these
approaches have shown promise in attracting regenerating axons onto the prosthetic
bridge. However, documented cases of axons traversing these conduits to reach the intact
tissue on the opposite margin of the lesion area are rare. Consequently, successes in
inducing axonal regeneration have not translated into appreciable recovery of function.
Nevertheless, despite the failure of significant axonal regrowth on existing bridges,
advances in generating conduits for growth across lesioned areas must be made to
successfully restore function after SCI.
In a simplified view, an ideal bridging neural conduit would be made from a
biocompatible material that contains either channels or fibers that spatially guide
regenerating axons. Since damage to the spinal cord induces necrosis that frequently
affects multiple fiber tract systems, this bridge should fill the extent of the cyst area.
Additionally, it should have a level of porosity that allows the inward migration and
incorporation of supportive cells as well as the traversing axons. Finally, the ideal bridge
should have the capacity to deliver signaling factors in a controlled manner to aid in the
attraction, directional growth, and viability of traversing regenerating axons. One
technique that has the capacity to generate such an ideal bridging prosthesis is
electrospinning. Similar in concept to electrospraying, electrospinning uses a highvoltage electric field to generate extremely fine fibers that are deposited on a grounded
collector to form a nonwoven mat (Bowlin et al., 2002). Chemically, these mats can be
electrospun from either extracellular matrix (ECM) proteins or synthetic polymers, both
of which can be spun alone or in combination with other growth-promoting factors.
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Physical properties of these matrices, such as fiber diameter, porosity and alignment can
also be controlled (Fridrikh et al., 2003). In the field of tissue engineering, the
application of this technique has resulted in the generation of several biocompatible
substrates such as growth-promoting dermal implants, cardiac patches, and synthetic
vessels (Stitzel et al., 2001; Sun et al., 2005). For example, studies show that interstitial
fibroblasts and endothelial cells migrate readily into an implanted electrospun collagen
matrix from surrounding tissue (Telemeco et al., 2005). Once there, these cells
proliferate and actively remodel this biological substrate, resulting in accelerated wound
repair with less contracture. More recently, electrospinning has been used to generate
growth matrices for cortical stem cells (Yang et al., 2005). Collectively, these studies
indicate the potential utility of electrospining to create biocompatible substrates for use in
injury repair.
In the study presented in this chapter, we examined the potential use of
electrospinning to engineer a polarized matrix for axonal guidance. This matrix, which
was spun from the resorbable suture material, polydioxanone (PDS), was tested for
biocompatility with cells of neuronal and glial origin, and the growth dynamics of these
cells on the matrix were assessed in cell culture studies. These experiments demonstrate
that both the directionality and exuberance of axonal growth are controlled significantly
by the physical and chemical properties of the underlying electrospun substrate.
Controlling these two parameters of axonal growth are prerequisites to establishing a
successful strategy for bridging lesioned areas in SCI.
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Materials and Methods
Electrospinning
Electrospun matrices were fabricated from the PDS II violet monofilament
surgical suture (Ethicon) as described previously (Boland et al., 2005). Briefly, for each
matrix, 150 mg of 10% weight/volume of cut PDS filament was dissolved overnight in
the solvent 1,1,1,3,3,3-hexafluoro-2-propanol. The solution was then transferred to a 5-ml
syringe tipped with an 18-gauge blunt-end needle (Kontes) and the syringe mounted onto
a syringe pump set at a delivery rate of approximately 30 ml/hr. The needle was
connected via a wire outfitted with an alligator clip to the positive output lead of a high
voltage direct current (DC) power supply (Spellman CZE1000R) set to 22 kV. The
grounded rectangular mandrel, with a cross-section of 10 × 3 mm, was placed 20 cm
from the needle (Figure 2.1). An electric field was generated across the nozzle and the
grounded mandrel, inducing a jet of solution to be drawn out from the syringe and
resulted in the deposition of a solid fiber core onto the rotating mandrel (Taylor, 1964).
By varying the rotation rate of the mandrel, as determined by a calibrated digital
stroboscope (Shimpo Instruments DT-311A), aligned and random fibers with diameters
of 2 to 3 mm could be generated (Figure 2.2). Specifically, a faster rotation rate of 5000
rpm was used to spin matrices of aligned fibers (aligned matrices) whereas a slower
rotation rate of approximately 10 rpm or less generated randomly oriented fibers (random
matrices). Additionally, an even distribution of the fibers on the mandrel was achieved
by allowing the mandrel assembly to translate (0.5 Hz).
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Scanning electron microscopy
To prepare the matrices for scanning electron microscopy (SEM), 1-mm squares
of both aligned and random matrices were cut from the electrospun mat and sputtercoated in gold. Photomicrographs (750 ×) were taken of random areas in each matrix,
digitized with a flatbed scanner, and analyzed for fiber alignment using 2-dimensional
fast Fourier transform (2D FFT).

2-Dimensional Fast Fourier Transform Alignment Analysis
As previously described by this laboratory (Alexander et al., 2006), utilizing the
FFT function of the ImageJ image processing software, an image containing a graphical
representation of the frequency content was generated from a digitized, square, grayscale
image of the elements to be analyzed. Pixel intensities and the distribution of the
intensities (frequency content) of this output image correlate to the directional content of
the original image. Pixel intensities were summed along a radius from the center to the
edge of the image to quantify the relative contribution of objects oriented in that
direction. This summing was repeated at 1° increments around the image and the 360
summations were plotted. In this manner, a 2D FFT of an image containing randomly
oriented elements results in relatively constant pixel intensities independent of direction.
Theoretically, a radial summation of this type of data set should be represented as a flat
line; however, because of edge effects associated with square images, an undulating plot
with four small, symmetrical peaks results. In contrast, a 2D FFT of an image that has
elements that are aligned preferentially would result in higher pixel intensities along the
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aligned direction. Accordingly, when the radial summations are plotted, two peaks,
representing the two angles (180° apart) associated with the aligned elements in an image
are generally seen (Ayres et al., 2006, 2008).

Dorsal Root Ganglia Isolation and Culture
In this study, the potential of aligned matrices to influence the growth dynamics
of extending dorsal root ganglion (DRG) neurites was tested. A set of random matrices
was used as controls. In accordance with the Virginia Commonwealth University
Institutional Animal Care and Use Committee, DRGs were dissected from embryonic day
16 (E16) Sprague Dawley rats as described previously (Sharma and Bigbee, 1998).
Briefly, following removal from the uterus, the developing spinal cord from each embryo
was exposed anteriorly. The entire cord was dissected from its rostral end and placed in
Leibovitz L-15 media with 10% fetal bovine serum (FBS). The attached DRGs were
then plucked off with fine tip forceps.
Circles of aligned and random matrices of 8-mm in diameter were sterilized in
100% ethanol, rinsed in Hank’s balanced salt solution, and secured on the bottom of a 35mm diameter Petri dish using hypodermic needles. Using a dissection microscope,
several DRGs were micropipetted onto each matrix and pinned in place with 0.15-mm
diameter minuten pins (Austerlitz). Cultures were incubated at 37°C with a 95% air/5%
CO2 gas mix in Eagle’s minimum essential medium with glutamine supplemented with
10% glucose, 5% FBS and 0.01% 2.5 S nerve growth factor. The medium was changed
every 2 d, alternating between the above medium and medium containing the antimitotic
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agent, 5-fluorodeoxyuridine (10-5 M), which limits the proliferation of Schwann cells in
DRG cultures (Wood, 1976). Following a 10-d incubation, the cultures were fixed in 4%
paraformaldehyde in 0.1 M phosphate-buffered saline (PBS). Following fixation, DRG
cultures were immunostained for the β-tubulin neuronal marker TuJ1 (Covance). Cultures
were first blocked for 30 min in a solution consisting of PBS with 10% FBS and 0.3%
Triton X-100, incubated for 2 h in a 1:500 dilution of TuJ1 mouse primary antibody in
PBS and visualized with a 1:200 dilution of Alexa Fluor 488 goat anti-mouse secondary
antibodies (Invitrogen) in PBS. Subsequently, 6 × digital, wide-field, fluorescence
images of the DRG and its neuritic outgrowth were obtained using an Olympus BX51
microscope. For this study, DRGs were pinned on at least six matrices (three aligned and
three random) and the experiment was repeated at least three times.

Astrocytic isolation and culture
In this study, the potential of aligned matrices to influence growth dynamics of
astrocytes was tested. A set of random matrices was used as control. In accordance with
the Virginia Commonwealth University Institutional Animal Care and Use Committee,
rat primary astrocytes were isolated using methods described previously (McCarthy and
de Vellis, 1980). Isolated postnatal day 3 (P3) rat cortices were minced and dissociated
mechanically and enzymatically. Cells were seeded into T-75 poly-L-lysine-coated
tissue culture flasks that contained Dulbecco’s modified Eagle medium/Ham’s F-12
medium, 10% FBS, and 1% antibiotic-antimycotic agent, and allowed to proliferate until
the population reached confluency. During this time, media changes were made every 3

36

to 4 d. To purify the resulting mixed glia culture upon confluency, cultures were shaken
overnight in an incubator to remove non-adherent cells. Two cycles of treatment with the
selective replication inhibitor cytosine arabinoside were carried out subsequently to
further purify the astrocytic population.
Circles of aligned and random matrices were placed into 10-mm diameter culture
wells and seeded with enzymatically dissociated astrocytes at a concentration of 104
cells/ml. Cultures were incubated for 7 d in the astrocyte media described above and
fixed using 4% paraformaldehyde. Following fixation, astrocyte cultures were
immunostained for the astrocytic marker, glial fibrillary acidic protein (GFAP) (DAKO).
Cultures were incubated for 2 h in a 1:1000 dilution of the GFAP rabbit primary antibody
in PBS and visualized with a 1:200 dilution of Alexa Fluor 568 goat anti-rabbit secondary
antibodies (Invitrogen) in PBS. Images of astrocytes grown on aligned and random
matrices were obtained with a Leica TCS-SP2 AOBS confocal microscope. For this
study, astrocytes were seeded on at least six matrices (three aligned and three random)
and the experiment repeated at least three times.

Astrocytes-Dorsal Root Ganglia Co-culture
To test the extent to which astrocytes affect the growth of DRG neurites on
electrospun PDS matrices, DRGs were co-cultured with astrocytes that were first seeded
on matrices as outlined above. Specifically, astrocytes were grown on either aligned or
random matrices for 10 d until confluent. DRGs were then pipetted onto these astrocyteseeded matrices, pinned down and cultured for an additional 10 days.
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Immunocytochemistry was performed using a primary antibody cocktail of GFAP
and TuJ1, and confocal images obtained for analysis. To determine the length of DRG
neuritic outgrowth on aligned matrices with and without astrocytes, a distance
measurement was made from the center of the DRG to the furthest extent of overall
neuritic outgrowth. Student’s t-test was used to determine statistical significance. For
this study, astrocytes and DRGs were seeded and pinned respectively on at least six
matrices (three aligned and three random) and the experiment repeated at least three
times.

Results
Using the apparatus shown in Figure 2.1, PDS was electrospun onto a mandrel
with a rotation speed of either 5000 rpm or approximately 10 rpm to fabricate matrices
containing fibers with varying degrees of alignment. SEM was then used to visualize the
extent to which a mandrel speed of 5000 rpm generates aligned fibers (aligned matrix)
and a mandrel speed of approximately 10 rpm generates randomly orientated fibers
(random matrix). Although the difference in fiber alignment between the two types of
matrices was evident at the SEM level (Figure 2.2A and D), a more objective
determination of alignment was desirable to establish whether fiber alignment was
significantly different. To achieve this, we employed a 2D FFT methodology. Such an
approach quantitatively analyzes the extent to which the population of fibers in the matrix
is aligned with respect to each other, thereby establishing a general direction of alignment
of the entire fiber population. After executing the algorithm on a converted grayscale
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SEM image cropped down to a square (Figure 2.2A and D), the immediate output of a 2D
FFT is a frequency spectrum (Figure 2.2B and E). The distribution of the pixels in the
frequency spectrum can be used to evaluate fiber alignment in an original data image. A
data image containing random elements produces a frequency spectrum with pixels
distributed about the center in a symmetrical distribution (Figure 2.2B). Conversely, a
data image containing aligned elements produces a frequency spectrum with pixels
distributed in an elongated ellipse (Figure 2.2E). Figure 2.2C and F are graphs of a 2D
FFT analysis on representative images of a random and aligned matrix, respectively. The
height and width of the peaks indicate the uniformity of fiber alignment. The axis of
distribution of the pixels in the frequency spectrum reports the principal axis of
orientation (Ayres et al., 2006, 2008). Fibers electrospun at a high mandrel speed were
displayed graphically as having a dominant orientation toward a specific direction
(approximately 180°, or a vertical orientation, in this case), thereby indicating a
significant degree of alignment for the general fiber population. In contrast, for a random
matrix, the presence of four small symmetrical peaks (associated with edge artifact)
indicates that there is no preferential alignment. Moreover, the degree of fiber alignment
in both types of matrices is consistent between electrospun samples fabricated for this
study and those used in subsequent experiments.
After confirming the matrix alignment, DRGs were pinned to matrices, cultured
for 10 d, fixed and immunolabeled for the TuJ1 neuronal marker. Representative, lowpower, fluorescent images of the DRGs on aligned and random matrices showed different
patterns of neuritic outgrowth (Figure 2.3). On a random matrix, neurites grew radially
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outward from the ganglion without preference to any specific direction, generating a
round, spokes-of-a-wheel appearance (Figure 2.3A). In contrast, on an aligned matrix,
most neurites grew preferentially along a particular axis (Figure 2.3B). Using reflectance
confocal microscopy, it was confirmed that this axis of growth was in the same
orientation as the underlying fibers of the matrix (data not shown). Although a few
neurites were not oriented initially to the direction of the underlying matrix, most
eventually turned and continued their extension in the direction of the underlying fibers.
Additionally, neurites growing in the direction of the underlying matrix grew faster than
those growing perpendicular to the aligned fiber axis or on random matrix.
An observation that is not apparent in these images but evident in cultures grown
for extended periods is that neurites began to show signs of cellular deterioration, such as
the presence of membrane blebbing and vesiculation (Figure 2.6A). These changes are
common in neurons grown in vitro for extended periods in the absence of supportive or
ECM substrata. Considering this and the fact that the matrices are generated from a
resorbable material (PDS) that dissolves with time, we hypothesized that a glial substrate
might provide a more stable, supportive interface between the resorbable matrix and the
outgrowing neurites. Accordingly, astrocytes purified from P3 rat cortices were seeded
onto aligned and random matrices and grown for 7 d. Subsequently, the matrices were
fixed and immunolabeled for the astrocytic marker GFAP. Confocal images of astrocytes
grown on both types of matrices show that these cells grew readily on electrospun PDS
(Figure 2.4). However, astrocytes grown on a random matrix extend processes that are
positioned more randomly (Figure 2.4A and C). This is in striking contrast to astrocytes
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grown on an aligned matrix (Figure 2.4B and C), for which process extension mirrors the
orientation of the underlying fibers.
To test the extent to which astrocytes might improve the growth of DRG neurites
on electrospun PDS matrices, DRGs were grown on matrices pre-seeded with astrocytes.
First, dissociated astrocytes were seeded on aligned and random matrices and incubated
for 10 d before DRGs were pinned onto the astrocyte-seeded matrices and incubated for
10 d. Subsequently, the matrices were fixed and dual-immunolabeled for TuJ1 and
GFAP. Following 20 d of growth, astrocytes seeded on both matrices extended longer
processes than after only 7 d of growth (Figure 2.5A and C). Moreover, astrocytic
processes were aligned to match the orientation of the underlying PDS fibers within each
matrix, which is consistent with a shorter culture period. DRGs grown on a substrate of
randomly-oriented astrocytes grew radially outward from the ganglion without preference
to any specific direction (Figure 2.5A and B). Conversely, DRGs grown on a substrate of
aligned astrocytes (Figure 2.5C and D) displayed a similar alignment and extended longer
processes than when grown on a glia-free matrix (Figure 2.5F). Many of the neurites on
the aligned, astrocyte-seeded matrices reached the border of the matrix and continued
growing on its opposite side. In both cases (aligned and random), processes changed
direction readily to grow along astrocytic processes (Figure 2.5E). Moreover, DRGs
grown on either seeded matrix displayed less fasciculated outgrowth than observed on
PDS matrices alone and appeared to be more robust, as evidenced by the lack of
vesiculations and membrane blebbing (Figure 2.6).
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Discussion
In this study, we have examined the potential use of electrospinning to engineer a
polarized matrix for axonal guidance. By varying the rate of rotation of the mandrel,
matrices containing aligned fibers and randomly oriented fibers were fabricated from
PDS. The degree of fiber alignment was determined visually by SEM and quantified by
2D FFT analysis. Both neurons and astrocytes were grown separately and in combination
on these matrices to assess biocompatibility and growth dynamics. Specifically, when
E16 DRGs were placed on these matrices and allowed to grow for 10 d, the direction of
the projecting neurites matched the orientation of the underlying PDS fiber population.
Moreover, on aligned matrices, the length of neuritic outgrowth exceeded that seen on
random matrices. After 10 d in culture, however, neurites began to exhibit evidence of
necrosis. In view of this, we tested the extent to which cortical astrocytes are compatible
with these matrices and whether their presence affects DRG growth. When seeded on
these PDS matrices, astrocytes grew robustly and the orientation of process outgrowth
matched that of the underlying matrix. When DRGs were grown on these glial
substrates, they exhibited no evidence of necrosis and their neurites aligned with
astrocytes and displayed longer process outgrowth than on aligned PDS matrix alone.
Collectively, these experiments demonstrate the potential for electrospinning to generate
an aligned matrix that influences both the directionality and dynamics of DRG neuritic
growth.
In addition to generating an aligned matrix to influence the directionality of
neuritic outgrowth, the process of electrospinning can be manipulated further to generate
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matrices with additional characteristics that mimic more closely the in vivo environment
of the central nervous system (CNS). Specifically, ECM molecules such as collagen and
elastin remain biologically active when electrospun into matrices (Boland et al., 2004).
These experiments provide evidence that viable ECM molecules in the CNS can also be
electrospun into matrices to influence neuritic outgrowth. In our study, however, we
elected to use the synthetic molecule PDS as the solute for electrospinning because of its
proven biocompatibility, which is indicated by its inability to elicit an immune response,
and its structural stability in biological tissue. These characteristics prevent the matrix
from being remodeled in a manner that compromises its fiber polarity within a short time
frame, which is relevant when considering the use of this matrix to bridge lesioned areas
of the CNS. Specifically, the alignment of the fibers in the matrix will remain stable,
allowing regenerating axons sufficient time to cross the lesion into healthy target tissue.
Moreover, by seeding the PDS matrix with astrocytes, we have generated a cellular
bridge that retains alignment stability while providing crucial trophic support. In the next
two chapters, further modifications to the electrospinning process to generate a scaffold
that may be able to counter the inhibitory compounds seen after SCI as well as the testing
of these superior matrices are discussed.
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Figure 2.1. The electrospinning apparatus. Key system components include a solution
reservoir (syringe), nozzle (18-gauge, blunted, metallic needle), high-voltage DC power
supply, and grounded target (rotating mandrel).
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Figure 2.2. Generation of aligned and randomly oriented PDS matrix fibers. (A) SEM
shows more randomly oriented fibers in a representative random matrix, generated by
using a slower mandrel rotation speed (approximately 10 rpm). (B) Raw output of the 2D
FFT alignment analysis of a random matrix. The more radially symmetrical silhouette of
the 2D FFT is consistent with fibers that are oriented in random directions. (C) Radial
plot of the summations of relative pixel intensity at a radius versus the angle (°). The
periodicity of the graph is caused by the inherent symmetry of the raw 2D FFT output.
The smaller, broader peaks reflect a more random distribution of directionality. (D) SEM
showing more consistently oriented fibers in a representative aligned matrix that is
generated using a mandrel rotation speed of 5000 rpm. (E) Raw output of the 2D FFT
alignment analysis of an aligned matrix. The slender profile of the silhouette indicates
fiber alignment. (F) A taller, narrower peak at approximately 180° indicates the general
direction in which the fiber population is oriented. Scale bars (A and B) = 10 µm.
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Figure 2.3. Fiber alignment of the electrospun matrix is conferred to pinned DRGs.
Low-power, wide-field, fluorescent image of a representative DRG immunostained for
TuJ1 (green) on matrix fixed 10 d after pinning. (A) DRG on a random matrix fixed 10 d
after pinning. DRG neurites grown on a random matrix displayed a tortuous growth
pattern that reflects the underlying matrix. (B) In contrast to DRG grown on a random
matrix, neurites grew preferentially in one direction (vertical in this image) that reflects
the orientation of the underlying matrix fibers. Scale bars (A and B) = 200 µm.
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Figure 2.4. Fiber alignment of the matrix is conferred onto seeded astrocytes. Confocal
images of astrocytes, immunostained with GFAP (red), grown on a random (A) or
aligned matrix (B) for 7 d after seeding. In both instances, the orientation of the
underlying matrix fibers is conferred to the astrocytic processes. (C) The average peak
value of the 2D FFT analysis (radial plot) on astrocytes seeded on matrices. Astrocytic
process alignment on random and aligned matrices is statistically different (p = 0.004).
Scale bars (A and B) = 100 µm.
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Figure 2.5. Aligned astrocytes influence the directionality and length of DRG neuritic
outgrowth (A to D). Confocal images showing DRG neurites (green) grown on
astrocytes (red) seeded on either random (A and B) or aligned (C and D) matrices. In the
presence of randomly oriented astrocytes (B), the orientation of the neurites is radial,
growing out from the ganglion in all directions, whereas neurites grown on an aligned
astrocyte-seeded matrix (D) display a similar alignment. (E) High-power, wide-field,
fluorescent image showing that neurites change direction to grow along astrocytic
processes. (F) The length of DRG neuritic outgrowth on aligned matrices with or without
seeded astrocytes. Outgrowth is significantly longer (p = 0.008) when grown on
astrocyte-seeded matrices. Scale bars (A to D) = 100 µm. Scale bar (E) = 30 µm.
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Figure 2.6. DRGs on astrocyte-seeded matrices grew more robustly, as evidenced by
lack of vesiculation and fasciculation. DRGs grown for 10 days on (A) a PDS matrix
alone in the absence of astrocytes and (B) on an astrocyte-seeded PDS matrix.
Astrocytes cannot be visualized because of the filter selection for this fluorescent image.
Scale bars (A and B) = 10 µm.
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Chapter 3
Evaluating the Incorporation of Nerve Growth Factor and
Chondroitinase ABC into an Electrospun Scaffold by Utilizing
an Alginate Delivery System

Introduction
One of the many obstacles to spinal cord injury (SCI) repair following trauma is
the formation of a cyst that impedes axonal regeneration. Accordingly, as described in
the previous chapter, we examined the potential use of electrospinning to engineer an
implantable polarized matrix for axonal guidance. Briefly, in a series of in vitro studies,
we found that matrix alignment can be conferred to extending neurites, demonstrating the
potential for electrospinning to generate an aligned matrix that can be implanted into the
cyst so as to guide regenerating axons post-SCI.
However, many other obstacles hinder axonal regrowth in addition to the cyst. As
previously described, astrocytes within the SCI lesion site proliferate, hypertrophy, and
begin to express chondroitin sulfate proteoglycans (CSPG), which represent potent
inhibitors to axonal regeneration. At the neuronal level, axotomy of motor and sensory
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neurons results in the loss of neurotrophic support by target tissue, furthering the extent
of neuronal cell death. Additionally, the presence of myelin debris, as a result of
oligodendrocyte death, acts as a potent inhibitor to axonal regeneration. Collectively,
these cellular responses to SCI represent major impediments to axonal regeneration.
Mono-therapies that address each of these obstacles to regeneration individually have
resulted in only limited axonal regrowth and functional recovery. To date, no single
intervention has been devised to collectively address all of these obstacles to regeneration
after SCI.
In view of this, we hypothesized that our previously tested electrospun matrix can
be supplemented with compounds that can promote neuronal survival and neutralize the
growth-inhibitory proteins associated with gliotic scar. One crucial criterion for
optimizing axonal regeneration following SCI is to promote the survival of neurons
whose axons have been severed. It is well-known that neurotrophic factors are produced
in the central nervous system (CNS) following trauma (Dougherty et al., 2000; Krenz and
Weaver, 2000). Their presence mitigates injury-induced neuronal cell death and
promotes axonal plasticity and regeneration (Bregman et al., 1999; Zhou et al., 2003).
Furthermore, both in vitro and in vivo studies have begun to establish the extent to which
particular trophic factors stimulate axonal regeneration of the varying descending motor
tracts and ascending sensory systems of the spinal cord. For example, one particular
neurotrophic factor, nerve growth factor (NGF), is essential for the growth and survival
of several populations of sensory neurons that project axons through the spinal cord
(Tuszynski et al., 1994; Acosta et al., 2001). Accordingly, in a series of in vitro dorsal
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root ganglion (DRG) bioassays, NGF was incorporated into electrospun matrices with the
use of an alginate delivery system and the extent to which NGF remains bioactive was
assessed.
In addition, we sought to investigate the extent to which we could incorporate
other proteins into the matrix that could facilitate axonal regeneration. Specifically, it is
well-documented that following CNS injury astrocytes become reactive and begin to
express CSPGs, which are well-known inhibitors to axonal regrowth. Many in vitro and
in vivo studies have established that the enzyme chondroitinase ABC (ChABC) is capable
of inactivating the inhibitory functions of these proteins. Accordingly, in another series
of in vitro bioassays, ChABC was incorporated into electrospun and the extent to which
the enzyme remains bioactive was assessed.

Materials and Methods
Generation of Alginate Microspheres
Found in the cell walls of certain brown algae and seaweeds, alginate is a viscous
gum that is used in many industrial, food processing, and biomedical applications as a
waterproofing, thickening, or detoxification agent. Its apparent ease of gelation and
biocompatibility can be exploited, providing a delivery vehicle for NGF in our study.
Specifically, almost any protein of interest can be encapsulated in alginate microspheres
and dried and upon hydration, release their content in a sustained manner (Noushi et al.,
2005).
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Alginate microspheres were generated by electrospraying technique. A solution
of 0.05-mg/ml sodium alginate and 0.05-mg/ml protease-free bovine serum albumin
(BSA) (used as a carrier) was first produced and subsequently the solute of interest in the
quantity of interest was added to 1 ml of this solution. The solution was then loaded into
a 5-ml syringe tipped with an 18-gauge blunt-end needle (Kontes) and the syringe
installed onto a vertically mounted syringe driver such that the needle was pointed down
(Figure 3.1). The needle was connected to the anode of a high voltage direct current
(DC) power supply (Spellman CZE1000R) via a wire outfitted with an alligator clip. A
metal plate, which was connected to the cathode, was placed beneath the syringe driver.
A 150-mm glass Petri dish filled with 2% calcium chloride solution was placed on the
metal plate to facilitate collection of the alginate microsphere. Upon switching on the
power supply, the resulting electric field induced the formation of a fine aerosol mist of
alginate and upon contact with the calcium chloride solution, microsphere formation
takes place. Microspheres were collected and washed by centrifugation in a 2% calcium
chloride solution supplement with 10% isopropanol and finally pelleted and the supernate
removed. To further dry the alginate, the remaining sediment is diluted 1:4 in
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) by volume and the mixture is placed in a
syringe. At this point, the HFIP, being the densest liquid in the mixture will settle to the
bottom and it is subsequently dispensed, leaving the semi-dry alginate microspheres in an
interface layer just above. After dispensing the bulk of the HFIP, the tri-layered mixture
is deposited in another container and by way of yet another syringe and fine hypodermic
needle, the bottommost and topmost layers are removed to a greatest extent possible
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without disturbing the middle layer containing the microspheres. Finally, the remaining
middle layer is frozen in liquid nitrogen and subsequently lyophilized. The alginate is
ready for use after rehydration.
Although the collection rate is incredibly difficult to measure and a 100%
collection cannot be assumed, it is estimated that conservatively that we collect at least
50% of the microspheres that can potentially form. With that in mind, 5 µg of NGF
(Invitrogen) was incorporated into the alginate microspheres such that when
microspheres were allocated to individual cultures, the amount of NGF contained in the
microspheres would have the same order of magnitude as compared to the amount
contained in DRG culture media. In contrast, control microspheres were generated with
5 µg of protease-free BSA.

Dorsal Root Ganglia Isolation
DRGs were isolated from embryonic day 16 (E16) Sprague Dawley embryos as
described previously in Chapter 2. Briefly, embryos were removed from the uterus of a
gravid rat and dissected open anteriorly to expose the developing spinal cord. The entire
cord was then dissected free from its rostral end and placed in Leibovitz L-15 media with
10% fetal bovine serum (FBS). The attached DRGs were then plucked off with fine tip
forceps.
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Nerve Growth Factor Bioassay
To test the effectiveness of using alginate to deliver NGF, dissected DRGs were
placed into poly-L-lysine-coated wells of a 48-well plate. Each batch of alginate
microspheres were rehydrated in culture media. Assuming 50% collection, as previously
discussed, a volume of media containing a desired quantity of NGF, which is
incorporated in the microspheres, can be calculated. After ensuring a uniform
distribution of the microspheres, a calculated volume containing microspheres having a
desired quantity of NGF that would ultimately provide a concentration of 0.3 µg/ml in the
culture was transferred into Transwell membrane inserts and the inserts were placed in
wells containing DRGs. In normal DRG culturing conditions, a concentration of 0.1
µg/ml is used. Since the microspheres do not release their contents all at once, a higher
starting concentration was desired. Microspheres containing BSA were similarly
deployed to act as controls. Incubation media consisted of Eagle’s minimum essential
medium with glutamine supplemented with 10% glucose and 5% FBS. Additional
negative and positive controls were set up by incubating DRGs with NGF-free and NGFcontaining media, respectively. A schematic of the experimental setup is shown in
Figure 3.3. This assay was performed three times per animal with populations of E16 rat
DRGs from four different animals.
To visualize the DRGs, the cultures were first fixed in 4% paraformaldehyde and
subsequently immunolabeled for the β-tubulin neuronal marker TuJ1 (Covance) as
previously described in Chapter 2.
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To quantify the extent of growth exhibited by the DRG cultures, the area occupied
by the DRG neuritic processes was measured. Wide-field fluorescence images of the
DRGs were obtained and loaded into Adobe Photoshop. Using the “contrast” tool, the
contrast of the image is increased such that the colored pixels depicting neuritic processes
reach maximum color intensity. These pixels were then counted and since each pixel has
an equivalent area, an actual area can be estimated without bias.

Electrospinning
As before, polydioxanone (PDS) was again used to fabricate matrices in this
study. However, instead of using a rotating grounded mandrel, an air-gap electrospinning
system was adopted. Air-gap electrospinning utilizes two separate fixed grounded posts
in which the solution jet whips back and forth between the grounds, resulting in the
deposition of fibers between the posts. The rationale for migrating to this system is that
this methodology offers superior fiber alignment. In addition, this system allows for the
spinning of 3-dimensional cylinders, which is required when these matrices are ultimately
tested in animal models of SCI.
Briefly, for each matrix, a PDS filament was dissolved in the solvent HFIP at a
concentration of 125 mg/ml and the solution was deposited in a syringe, which was
mounted onto a syringe driver set to deliver 5 ml/hr. Though the exact placements of the
various electrospinning components differed between runs and required a bit of trial and
error for the optimal positioning of the two grounded posts, generally the air gap between

62

posts was set between 3 to 5 cm and the assembly containing the posts was placed no
more than 20 cm away from the nozzle.

Chondroitinase ABC Bioassay
To test the extent to which ChABC remains bioactive when the enzyme is
electrospun into matrix directly, a stripe bioassay was employed. Aggrecan, a CSPG
known to inhibit axonal growth (Lemons et al., 2003), was deposited in stripe lane
fashion via a micropipette onto poly-L-lysine-coated Thermanox cover slips. Upon the
drying of the aggrecan, DRGs were pinned onto the cover slips between the CSPG lanes
and the cover slips were placed in Petri dishes containing NGF-added DRG culture media
(formula described previously). ChABC (0.5 U per matrix) was mixed into the PDS
spinning solution and matrices were fabricated. After spinning, these matrices were cut
into small pieces such that each piece contained enough ChABC to supply a
concentration of 0.05 U/ml in culture conditions. After sterilizing in 70% ethanol, a
piece of the cut ChABC-containing matrix was placed in each experimental dish while a
piece of the cut BSA-containing matrix was placed in each control dish. A schematic of
the experimental setup is shown in Figure 3.5. This assay was performed three times per
animal with populations of E16 rat DRGs from four different animals.
To visualize the DRGs and aggrecan lanes, the cultures were first fixed in 4%
paraformaldehyde and subsequently immunolabeled for the β-tubulin neuronal marker
TuJ1 (Covance) and the CSPG marker CS-56 (Sigma). In addition to the staining steps
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outlined in Chapter 2, a denaturing step utilizing 2-M hydrochloric acid is included
before blocking.

Results
Once we established that electrospinning can be used to generate a biocompatible
bridge that provides directionality to axonal regrowth (Chapter 2), we next sought to
establish the extent to which proteins that facilitate regeneration can be incorporated into
the bridging matrix. First, we sought to supplement the matrices with a neurotrophin,
namely NGF, via the use of an alginate delivery vehicle. NGF-containing alginate
microspheres of uniform diameter were produced via electrospraying (Figure 3.2). To
test the effectiveness of using alginate to deliver NGF and the extent to which the
neurotrophin remains bioactive, DRGs, which are a clusters of neurons that convey
sensory information through the spinal cord and require NGF for their survival, were
cultured in wells of a 48-well plate under the following conditions: in the absence of
NGF in the media, in the presence of NGF in the media, in the presence of BSAcontaining microspheres, and in the presence of NGF-containing microspheres.
Following 3 d of incubation, DRG neurites displayed predictably scant outgrowth in the
absence of NGF (Figure 3.3B). In the presence of NGF in the culture media, neuritic
outgrowth was also unsurprisingly evident (Figure 3.3D). However, the NGF-induced
neuritic outgrowth was even more pronounced in cultures where DRGs were exposed to
NGF-containing alginate microspheres (Figure 3.3F). The readily apparent difference in
the extent of outgrowth between NGF in media and NGF supplied by the alginate is
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likely the result of the gradual increase in concentration of NGF in the media with time.
To quantify the extent of outgrowth exhibited by the DRG cultures, the area occupied by
the neuritic processes of each DRG was measured by counting pixels of digital images.
The group means of the estimated area occupied by a DRG are shown in Figure 3.4.
Finally, electrospun PDS matrices containing NGF-incorporated alginate microspheres
were fabricated and tested on DRG cultures and similar results were obtained (data not
shown).
We next sought to investigate the extent to which we can incorporate other
proteins of interest into the matrix that could facilitate axonal regeneration. Specifically,
as mentioned previously, ChABC has been shown in numerous occasions its ability to
elicit improved axonal regrowth and in some cases functional recovery following SCI by
neutralizing the inhibitory nature of CSPGs. In view of its success, we sought to
incorporate ChABC into electrospun matrices as another means of making the post-SCI
microenvironment more growth permissive. Since reactive astrogliosis and gliotic scar
formation have a longer time horizon, there needs to be a somewhat delayed yet sustained
release in order for ChABC to be useful. Accordingly, it was decided that ChABC be
incorporated directly into the PDS matrix during the electrospinning process. To test the
extent to which enzyme remains bioactive in the matrix, DRG neurons were cultured
between lanes of aggrecan, a known CNS CSPG, and an appropriately sized piece of
matrix incorporated with or without ChABC was placed in each culture. Following 7 d
of incubation, in the absence of the enzyme, DRG neurites avoided the aggrecan lanes
thereby demonstrating the extent to which CSPGs can inhibit axonal growth (Figure

65

3.5B). In contrast, DRGs grown in the presence of the enzyme, which is released from
the matrix, displayed no inhibition and readily grew across the aggrecan lanes (Figure
3.5D). These results demonstrate that the enzyme is released from the matrix in a
bioactive form and neutralizes the axon growth-inhibitory properties of CSPG.
Collectively, these studies point toward a novel approach by which a
biocompatible scaffold can be implanted into the fluid-filled cyst post-SCI, providing
regenerating axons with a directional path across the lesion site as well as trophic and
inhibitor-neutralizing support in a single package.

Discussion
One of the many pathologic obstacles of spinal cord repair following contusive
trauma is the formation of a fluid-filled cyst across which regenerating axons have to
traverse in order to reinnervate their distal targets. To this end, in Chapter 2, we
examined and demonstrated the potential use of electrospinning to engineer an
implantable directional matrix for axonal guidance. In view of the recognition that
successful SCI therapies require a multifaceted tactic, we proposed a novel approach of
incorporating into electrospun guidance matrices pharmacologic agents that can promote
neuronal survival and neutralize inhibitory molecules associated with the gliotic scar.
Specifically, NGF was encapsulated into electrospun alginate microspheres and the
extent to which this protein remains bioactive was assessed with DRG bioassays. These
microspheres were placed in Transwell membrane inserts over the ganglia so as to
provide the only source of NGF in the culture. Their presence supported vigorous
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neuritic outgrowth in contrast to control microspheres containing only albumin. The
bioactivity of NGF was similarly preserved when NGF-containing microspheres were
incorporated into electrospun matrices. We next sought to investigate the incorporation
of ChABC into the matrix as it has been previously shown that this enzyme can reduce
the axonal growth-inhibition of various CSPG. Stripes of aggrecan, a CSPG found in the
CNS, were placed on cover slips with DRGs pinned in between the inhibitory lanes. In
control cultures, DRG neurites did not extend onto aggrecan lanes. However, upon
exposure of the cultures to ChABC-incorporated matrices, the growth-inhibitory nature
of aggrecan was neutralized and neurites grew extensively across the stripes.
Collectively, these experiments point toward a novel SCI therapeutic approach of
generating electrospun scaffolds that can directionally guide axons across the lesion site
while providing trophic and inhibitor-neutralizing support.
A remarkable observation that was made in the present study was the dramatic
difference in the outgrowth pattern of DRGs when cultures were exposed to NGF in the
media versus NGF in the alginate microspheres. When DRGs were exposed to NGF in
the culture media, the DRG displayed a growth that was prototypical—neurites grew
radially and linearly outward from the ganglion and producing a round, spokes-of-awheel appearance. When DRGs were exposed to the alginate microspheres containing
the NGF, the neurites similarly grew outward radially from the ganglion. However, the
appearance of the neuritic processes in this experimental perturbation was not linear, but
highly branched. In these cultures, nearly all the neuritic processes were seen to
crisscross and overlap over and over at almost all locations occupied by the DRGs. Thus,
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in view of our attempt to measure the area occupied by the neuritic processes by way of
counting pixels in high resolution digital images and our subsequent detection of
quantitative differences in the amount of growth between experimental groups, we
surmised that we probably still underestimated the extent of growth in the culture
exposed to the alginate microspheres. Since the amount of microspheres that was
initially deposited in these experimental cultures was determined assuming a 50%
collection estimate after electrospinning, it was first suggested that the dramatic
outgrowth seen was perhaps due to a much higher concentration of NGF, which could
have potentially reached at much as six times the level used in the positive control culture
if the NGF was release all at once from the alginate. As introduced in the first chapter,
the low-affinity p75 neurotrophin receptor (p75NTR) may act as a sink for the excess
NGF and synergizes with the tropomyosin receptor kinase (Trk) receptor, specifically
TrkA, to produce the extraordinary branched pattern of DRG process outgrowth seen.
However, in a side experiment where DRGs were exposed to 10µg/ml of NGF (ten times
the normally used concentration), the branched pattern of outgrowth was not observed. A
second explanation is that perhaps the alginate may have some synergistic effect with the
NGF. Though no known mechanism would suggest that this would occur, we
nevertheless tested this hypothesis in yet another side experiment where DRGs were
exposed to NGF in the culture media while blank alginate microspheres were deposited
in the cultures. Again, only the typical radially linear outgrowth pattern was seen. A
third possibility that may cause the dramatic branching is that perhaps the neurons
respond to a gradual increase in NGF concentration in the media from the alginate
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release. Such an increase of neurotrophin may result in a temporal shift of the cellular
profile of activated receptors. The p75NTR, having low affinity to the neurotrophins,
would not bind the NGF early on during the experiment but would bind later when the
NGF concentration in the media increased. Though we did not attempt to prove this
hypothesis, this explanation can be established with a simple experiment where DRGs
would be exposed to a gradually increasing concentration of NGF.
Another notable observation involves the ChABC-CSPG stripe bioassays.
Though DRG neurites undoubtedly grew over the aggrecan lanes when exposed to
ChABC, the DRG processes displayed a webby fasciculated appearance. As mentioned
in Chapter 2, it is well-known that neurites often fasciculate when elongating on a less
than optimal substrate and that cell adhesion molecules and their interactions with the
substrate play a significant role in this response (Acheson et al., 1991; Honig and
Rutishauser, 1996; Tang et al., 1994). In an in vitro study, Snow et al. demonstrated how
DRG neurites readily fasciculate upon contact with locales containing very low
permissive concentrations of CSPGs, stayed fasciculated while elongating over such
areas, and defasciculated upon leaving the CSPG zone (2003). While ChABC was not
employed in the study completed by Snow et al., their results show that even a minute
amount of an inhibitor, though not able to outright prevent outgrowth over the inhibitory
areas, was able to cause neuritic fasciculation. In our study, ChABC cleaved the
glycosaminoglycan chains on the aggrecan molecules, which is known to reduce the
inhibitory nature of the CSPGs. However, though less understood, there are also direct
protein core effects, which may partially explain the fasciculation seen in our cultures.
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Hence, in our study, while the ChABC is able to reduce the inhibition of the aggrecan
such that outgrowth is possible on the CSPG lanes, the reduction is not enough to cause
defasciculated growth. Fasciculated growth is not necessary undesirable, as it has been
suggested that fasciculation may promote axonal pathfinding and prevent deviant
sprouting post-injury (Snow et al., 2003).
In the experiments outlined in this chapter, NGF was selected and tested in
bioassays experiments. However, the presence of NGF in the microenvironment postSCI has been shown to cause undesirable side effects such as autonomic dysreflexia and
neuralgia caused by the aberrant spouting of certain neurons (Krenz et al., 1999).
Autonomic dysreflexia is a condition characterized by an immense sympathetic discharge
caused by noxious stimuli that results in increased blood pressure via widespread
vasoconstriction. Neuralgia, also known as neuropathic pain, is pain that is not a result of
pain receptor activation. Both of these adverse conditions are debilitating and potentially
dangerous, with the former being a medical emergency. In view of this, we seek to
incorporate other factors into our matrices that may be beneficial post-SCI. Since we
have demonstrated that NGF can successfully be integrated into our matrices and
delivered, other factors can be incorporated to aid in the survival and resprouting of other
neuronal groups. Exogenous administration of brain-derived neurotrophic factor (BDNF)
and neurotrophin-3 (NT-3) have been found to preserve the neuroplasticity of
corticofugal fibers and in some cases led to functional recovery post-SCI (Namiki et al.,
2000; Iarikov et al., 2007). Additionally, insulin-like growth factor-1 (IGF-1), a
polypeptide with sequence homology to insulin released primarily by the liver in
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response to growth hormone that affects human cells almost ubiquitously, has been
shown to promote the growth of projecting axons and dendrites, synaptogenesis, and
neuroprotection (Niblock et al., 2000; Cheng et al., 2003; Ozdinler and Macklis, 2006;
Hung et al., 2007). Hence, these factors such as BDNF, NT-3, and IGF-1 can
concomitantly be delivered via alginate microspheres by way of an electrospun matrix
implant.
In other experiments outlined in this chapter, ChABC was selected to be
incorporated into our electrospun matrices so as to neutralize the CSPGs seen after SCI.
However, other axon growth-inhibitory molecules have also been identified. One
notorious group of inhibitors is found to be associated with central myelin. Members of
this group include Nogo-A, myelin-associated glycoprotein, and oligodendrocyte-myelin
glycoprotein (McKerracher et al., 1994; Chen et al., 2000; Kottis et al., 2002). All three
have been demonstrated through in vitro and in vivo studies to cause growth cone
collapse by their binding to the Nogo-66 receptor (Liu et al., 2002; Xie and Zheng, 2008).
In view of this, we seek to incorporate a compound into our matrices that can overcome
the inhibitory effects of these myelin-associated proteins. One such compound of interest
is bucladesine, which is a cell permeable cyclic adenosine monophosphate (cAMP)
analog. Also known as dibutyryl cAMP, this cyclic nucleotide has been shown to alter
the growth state of older neurons and induce axonal growth in the presence of myelinassociated inhibitors (Cai et al., 1999; Gao et al., 2003; Domeniconi and Filbin, 2005).
Accordingly, bucladesine is an excellent candidate for incorporation.
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Figure 3.1. The electrospraying apparatus is very similar to the electrospinning
apparatus. Key system components include a solution reservoir (syringe), nozzle (18gauge, blunted, metallic needle), high-voltage DC power supply, and grounded target.
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Figure 3.2. (A) A light microscopic image of alginate microspheres showing their
uniform diameter. (B) A wide-field fluorescence image of the same microspheres
showing the incorporation of a fluorescent protein. The white arrows point to the same
piece of debris, indicating the same field of view in both images. Scale Bars (A and B) =
10 μm.
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Figure 3.3. Bioassay assessing the bioactivity of NGF-incorporated alginate
microspheres on DRG outgrowth. DRGs were isolated from E16 rat embryos and
cultured in wells of a 48-well plate. Schematics (A, C, and E) of the experimental setup
and their corresponding results (B, D, and F) are shown. In the absence of NGF in the
media (A), predictably no outgrowth is seen (B). However in a positive control setup,
specifically in the presence of NGF in the media (C), neuritic outgrowth is evident (D).
Microspheres were deposited in a Transwell insert and placed into wells (E). Neuritic
processes of DRGs exposed to NGF-incorporated alginate microspheres showed
exuberant outgrowth as compared with the positive control (F). Scale Bars (B, D, and F)
= 500 μm.
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Figure 3.4. The extent of outgrowth exhibited by the DRG cultures when exposed to
various sources of NGF (in media or alginate microspheres) was quantified and shown
here. The difference in the extent of outgrowth between NGF in media and NGF
supplied by the alginate is likely the result of the gradual increase in concentration of
NGF in the media with time.
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Figure 3.5. Stripe bioassay of dorsal root ganglia (green) grown between aggrecan lanes
(red) for 7 d in culture. Aggrecan, a CSPG, is a known inhibitor of axonal regrowth
following SCI. Schematics of the stripe bioassays are shown with or without
incorporating ChABC into the matrix (A and C) and their corresponding results (B and
D). In the absence of ChABC, DRG neurites were inhibited from growing on aggrecan
lanes (A and B). In contrast, in the presence of a ChABC-incorporated matrix, the
growth-inhibitory nature of aggrecan was neutralized. Aggrecan lane boundaries marked
by arrows. Scale Bars (B and D) = 500 μm.
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Chapter 4
Preliminary Tests of Implanting Electrospun Matrices in a Rat
Spinal Cord Transection Model

Introduction
In Chapter 2, we presented data demonstrating the successful use of
electrospinning to generate biocompatible, implantable matrices that are able to direct
neuritic outgrowth. And in Chapter 3, we showed how these matrices can be enhanced to
address the two specific therapeutic obstacles of neurotrophic support and increased
chondroitin sulfate proteoglycan (CSPG) expression after spinal cord injuries (SCI) by
supplementing the matrices with a growth factor and an enzyme that neutralizes the axon
growth-inhibitory activity of CSPGs. In view of these successes, we next sought to
examine the extent to which these matrices perform when implanted into a rat model of
SCI. In this brief chapter, we present a bit of preliminary results showing some initial
successes of this in vivo study.
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Materials and Methods
Electrospinning
Air-gap electrospinning was similarly employed in order to fabricate cylindrical
conduits of aligned fibers as described previously in Chapter 3 and the suture material
polydioxanone (PDS) was again used. Briefly, for each matrix, a PDS filament was
dissolved in the solvent HFIP at a concentration of 125 mg/ml and the solution was
deposited in a syringe, which was mounted onto a syringe driver set to deliver 5 ml/hr.
Though the exact placements of the various electrospinning components differed between
runs and required a bit of trial and error for the optimal positioning of the two grounded
posts, generally the air gap between posts was set between 3 to 5 cm and the assembly
containing the posts was placed no more than 20 cm away from the nozzle. To match the
size of the thoracic cord in a rat, spinning continued until a diameter target of 2 mm was
reached during the fabrication process.

Animal Model and Surgical Procedures
Adult Long Evans Hooded rats aged approximately 70 days were used for this
study. Owing to extensive experience with the rat percussive SCI model, we learned that
the presentations of cystic cavities that formed post-injury were highly inconsistent.
Furthermore, the extent of white matter sparing was equally variable. Therefore, in this
study, we elected not to use the percussive SCI model. Though we hope that these
electrospun matrices would in the future be used to bridge the fluid-filled cyst after
contusion SCIs in humans, we wanted an experimental animal model that would present
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consistent complete injuries so that our testing conditions of these electrospun matrix
implants would be as uniform as possible from animal to animal. Accordingly, a
transection SCI model was selected instead.
Adult Long Evans Hooded rats aged approximately 70 d were used for the
transection SCI protocols. All surgical and postoperative care procedures were
performed in accordance with the Virginia Commonwealth University Institutional
Animal Care and Use Committee. Animals were placed in a closed container, sedated
with 5% isoflurane, endotracheally intubated, and maintained under 2.5% isoflurane
during surgical procedure. Depth of anesthesia was assessed periodically during the
surgical procedures by tail pinch and watching for reflexive movements. Body
temperature was kept normothermic using a homeothermic blanket placed under the
animal. Employing sterile techniques, a dorsal midline incision was made over the midthoracic spine and a standard thoracic level 8 (T8) laminectomy was performed on the
animal to expose the spinal cord (Figure 4.1A). A 2-mm segment of the cord was then
completely removed via transection by iridectomy scissors, leaving a similarly sized gap
(Figure 4.1B). Thrombin-soaked foam pieces were placed in and around the created gap
to hasten hemostasis. After bleeding slowed (usually after about 15 to 20 min posttransection), an electrospun PDS matrix conduit was custom-fitted into the gap and
approximated to the cut cord stubs such that the fiber grain of the matrix ran
longitudinally with the cord (Figure 4.1C). The wound was closed in layers with silk
sutures and skin incision closed with surgical staple clips. Animals were subsequently
allowed to recover in a separate area containing a warming blanket.
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All animals received prophylactic gentamicin (5 mg/kg) before surgery and daily
thereafter for 7 d. Post-operatively, all animals were given easy access to food and water
and housed two per cage. Analgesic medication (acetaminophen oral suspension, 2
mg/ml) was mixed into the drinking water and administered for the first 3 d post-injury.
Manual bladder expression was performed three times daily for the first week after
surgery and two times daily thereafter until spontaneous micturation was reestablished.
Due to the severe nature of transection cord injuries, spontaneous micturation generally
did not occur in animals until the eighth week post-surgery.

Preliminary Results
At the end of week 1 and week 6 post-surgery, animals were sacrificed and their
spinal cord containing the electrospun implant was isolated. Grossly, the implant was
well integrated into the cord with excellent implant-stub adherence (Figure 4.2A). These
cords were cryosectioned longitudinally and the sections were labeled with the cell
nuclear fluorescent stain DAPI (4’,6-diamidino-2-phenylindole). At the end of week 1
post-surgery, growing tissue has enveloped the implant and cells are seen infiltrating the
implant from all sides (Figure 4.2B). By week 6 post-surgery, the matrix implant is
almost packed full of cells (Figure 4.2C). These results demonstrate the biocompatibility
and the capacity of the electrospun matrix conduit to facilitate cellular infiltration, an
important step in the bridging of gaps and cysts post-SCI. We are currently carrying out
other histological and behavioral assessment experiments to determine the extent of
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implant penetration by regrowing axons and recovery of motor functions. For these
experiments, enhanced matrices such as those described in Chapter 3 are being tested.
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Figure 4.1. Photographs showing the matrix implantation portion of the surgical
procedure. (A) The spinal cord (arrow) is exposed after completing a laminectomy at the
T8 level. (B) A gap (arrow) remains after 2 mm of the cord is removed via transection.
(C) Placement of a similarly sized cylinder of electrospun matrix (arrow) into the gap.
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Figure 4.2. (A) Gross view at week 6 post-surgery of a transected cord implanted with
an electrospun matrix conduit. (B) A representative longitudinal cord section labeled
with a fluorescent cell nuclear marker DAPI showing excellent integration of the matrix
(arrows) into the cord by the end of week 1 post-surgery. Cells are seen infiltrating the
matrix from all sides. (C) By week 6 post-surgery, the matrix (arrows) is almost packed
full of cells. Scale Bars (A) = 2 mm. Scale Bars (B and C) = 500 µm.
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Chapter 5
Chronicling the Injury-Induced Proliferative Response at the
Spinal Cord Injury Lesion Site and Attenuating the Response
with X-Irradiation

Introduction
Traumatic injury to the spinal cord results in the proliferation of cells at the lesion
site that mature into astrocytes, ultimately resulting in the formation of a gliotic scar. The
cells within the scar, of which the majority are astroctyes, express factors that are known
to inhibit axonal regeneration. In addition, as a result of the tight spatial cellular
associations of the scar, regrowing axons are prevented from crossing the scar toward the
opposite margin of the lesion. Consequently, the scar presents both a biochemical and to
a lesser extent physical barrier to axonal regeneration following spinal cord injury (SCI).
It is believed that the attenuation of this injury-induced cell population may be helpful in
reducing the inhibitory nature of the scar so as to allow a greater extent of regeneration
(Moon and Fawcett, 2001; Woerly et al., 2004; Tian et al., 2006). Furthermore, gliotic
scar attenuation may be a necessary adjuvant treatment to the implantation of a bridging
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scaffold since the scar represents on-ramp and off-ramp barriers to axonal regrowth onto
and off of the bridge. The attenuation of cellular proliferation needs not be extreme,
since, as previously noted, the gliotic scar features a number of important beneficial
effects, such as the isolation of damaged tissue from viable tissue and its notable role in
providing a substrate for angiogenesis.
Accordingly, using a rat percussive cord injury model and employing
immunohistochemical and flow cytometric methods by means of various cellular
proliferation and glial cell markers, we first identified the injury-induced cell populations
in and around the SCI lesion site and subsequently chronicled their initial periods of
proliferation. Once this information was obtained, we next sought to demonstrate the
extent to which this proliferative response can be attenuated with methods that target
dividing cells. Specifically, as previously shown by this laboratory and others, cellular
proliferation can be attenuated by appropriate levels of ionizing irradiation, a very similar
procedure which has been applied for decades to control malignant cells in cancer
therapy. Irradiation therapy possesses a number of desirable characteristics in that it is
non-invasive, reproducible, and accurate in its targeting. The use of irradiation as an
adjunctive therapy for SCI is not entirely novel. A very small number of published
studies have previously demonstrated mixed results in attenuating scar formation and
improving motor function (Kalderon et al., 2001; Pinjuh and Bedi, 2003; Ridet et al.,
2000; Zeman et al., 2001; Zhang et al., 2005). A reason for the inconclusiveness of these
studies perhaps may be attributable to the irradiation dosing, which was sometimes orders
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of magnitude apart between studies. Furthermore, the timing and frequency of doses
given often varied greatly between methodologies.
In view of these apparent deficiencies, a serial series of related experiments was
completed systematically so that the best timing and dose can be determined. As
previously stated, a chronicling of the injury-induced proliferative response after SCI was
first accomplished. This was done to establish the timing component. Before initiating
the irradiation experiments, exhaustive dosimetry was completed with the assistance of
the Division of Radiation Physics and Biology in the Department of Radiology. In order
to obtain dosing response and efficacy in neural tissue, the irradiation method was first
tested on a model of normal cellular proliferation in neural tissue, namely the
subventricular zone (SVZ) of neonatal rats, which contains a large number of dividing
cells. Later, the paradigm was further tested on an injury-induced cellular population in a
cortical stab injury rat model before ultimately tested on a contusion SCI rat model.

Materials and Methods
Mixed Glia Isolation and Culture
Before proceeding to in vivo experimentation, the reliability of employing flow
cytometry to count glial cells required confirmation. In view of this, unpurified glial
cultures were first used to test the flow cytometric methodology. In accordance with the
Virginia Commonwealth University Institutional Animal Care and Use Committee, glial
cells were isolated using similar methods described previously (McCarthy and de Vellis,
1980). Briefly, isolated postnatal-day 3 rat cortices were minced and dissociated
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mechanically and enzymatically. Cells were seeded into T-75 poly-L-lysine-coated
tissue culture flasks that contained Dulbecco’s modified Eagle medium/Ham’s F-12
medium with 10% fetal bovine serum and 1% antibiotic-antimycotic agent, and allowed
to proliferate until the population reached confluency. During this time, culture media
changes were made every 3 to 4 d. Cultures were ready for use after splitting.

Flow Cytometry
Flow cytometric methods were carried out using similar procedures described
previously (Bilsland et al., 2006). Glial cultures were trypsinized, resuspended, fixed
with 4% paraformaldehyde, and permeabilized with Cytoperm (BD Biosciences). Cells
were first labeled with 7-aminoactinomycin D (7-AAD) to identify cells from debris and
subsequently labeled with fluorochrome-conjugated antibodies for the thymidine analog
and marker of proliferating cells bromodeoxyuridine (BrdU) and for the glial markers
vimentin and glial fibrillary acidic protein (GFAP). Negative control antibodies were
used to facilitate the setting of quadrant gates.

Animal Model and Surgical Procedures
Adult Long Evans Hooded rats aged approximately 70 d were used for the
contusion SCI protocols. All surgical and postoperative care procedures were performed
in accordance with the Virginia Commonwealth University Institutional Animal Care and
Use Committee. Animals were endotracheally intubated and maintained under inhalation
anesthesia (2.5 % isoflurane) during surgical procedure. Depth of anesthesia was
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assessed during surgical procedures by tail pinch and observation for reflexive
movements. Body temperature was kept normothermic using a homeothermic blanket.
Employing sterile techniques, a dorsal midline incision was made over the mid-thoracic
spine and a standard thoracic level 8 (T8) laminectomy was performed (Figure 5.1B).
Animals were then placed in a spinal frame and the exposed spinal cord was contused
with the Multicenter Animal Spinal Cord Injury Study (MASCIS) impactor using a 10-g
weight dropped from a height of 25 mm (Figure 5.1A and 2.1C). Sham animals
underwent laminectomy but did not receive spinal cord contusions. The reproducibility
of the computer-driven MASCIS impactor can be assessed by examining the impact
parameters acquired by the computer during each trial, which includes the trajectory of
the falling rod, impact velocity, cord compression distance, and cord compression time.
Animal injuries with unacceptable impact parameters were excluded entirely from the
study. The wound was closed in layers with sutures and skin incision closed with
surgical staple clips. Animals were subsequently allowed to recover in a separate area
containing a warming blanket. For the irradiation studies, the impact site location was
noted via a single exclusive suture tied through skin and muscle layers dorsal to the
laminectomy site.
All animals received prophylactic gentamicin (5 mg/kg) before surgery and daily
thereafter for 7 d. Post-operatively, all animals were given easy access to food and water
and housed two per cage. Analgesic medication (acetaminophen oral suspension, 2
mg/ml) was mixed into the drinking water and administered for the first 3 d post-injury.
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Manual bladder expression was performed three times daily for the first week after
surgery and two times daily thereafter until spontaneous micturation was reestablished.

Chronicling the Glial Cell Proliferation at Lesion Site
To establish the time course of the injury-induced proliferative response after SCI
and relate this to gliotic scar formation, animals were first divided into two groups of
sham and injured. Subsequently, they were subdivided further (n = 3) as to the day postinjury (day 1, 2, 3, 4, 7, 10, and 14) an animal would receive two doses, 12 h apart, of
BrdU (300 mg/kg body weight). On day 14 post-injury, animals were sacrificed with a
lethal dose of pentobarbital and transcardially perfused with phosphate buffered saline
(PBS). The 5-mm spinal cord segment containing the SCI lesion epicenter was harvested
and the tissue was mechanically dissociated by passage though a 70-µm filter. The
resulting cell suspension was washed with PBS and the unwanted erythrocytes were lysed
with tris-buffered ammonium chloride. The cells were then prepared as described
previously for flow cytometric analysis.

X-Irradiation
To assess the extent to which X-irradiation can attenuate the normal proliferative
response in neural tissue, the SVZ of neonatal rats, which is an area in the brain
containing large numbers of dividing cells, was unilaterally irradiated via a Faxitron
43855D X-ray irradiator with varying single doses (5, 10, 15, and 20 Gy). (Irradiator
dosimetry was completed with film before experiments proceeded.) When it was
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determined that 15 Gy was the lowest dose that can attenuate 80% of the proliferative
response (data not shown) as compared to the SVZ of the control hemisphere, the use of
irradiation was further explored in injury-induced cellular proliferation model,
specifically in a cortical stab injury in rats.
After determining the peak period of proliferation via the chronicling experiment
described above, another group of SCI animals (n = 3) received a single dose of
irradiation administered on day 2 post-injury. To prepare the animal for the irradiation
procedure, the rat was first anesthetized with a mild dose of ketamine/xylazine cocktail
and placed in a small box. The dorsum of the animal was raised with a paper towel roll
placed beneath its upper abdomen. To protect the other tissues for irradiation damage, a
2-mm thick solid lead plate containing a square opening of 2.5 cm by 2.5 cm was placed
over the animal, with the center of the opening aligned with the laminectomy site as
noted by an exclusive suture that was tied during the wound closure after surgery. The
box containing the animal was then placed into the irradiator and a dose of 15 Gy as
determined by the duration of exposure (about 14 min) administered. After the exposure,
the animal was allowed to recover.

Results
Though the ultimate goal is to examine the approach of using X-irradiation to
reduce gliotic scar formation after SCI, a series of experiment was planned to determine
the appropriate dose and timing of the therapy. In order to establish the appropriate dose
of the irradiation, various doses were first tested on a model of normal cellular
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proliferation in neural tissue. Based on previous experience of the procedure in our
laboratory (McGinn et al., 2008), four different doses of irradiation (5, 10, 15, and 20 Gy)
were tested on the SVZ of neonatal rats, which contains a large number of dividing cells.
It was found that 15 Gy sufficiently attenuated the proliferative response by 80% (data
not shown). Subsequently, the use of irradiation was further tested on an injury-induced
cellular proliferation model, specifically a cortical stab injury in rats. In this experiment,
rats were given a needle stab injury to the cortex, inducing the cells in the vicinity to
proliferate (Figure 5.2A). In contrast, rats that were then irradiated at the site of injury
when cells began to proliferate at day 2 post-injury showed the presence of only few
dividing cells (Figure 5.2B).
Now that the dosing of irradiation was established, we wished to explore when
such a dose should be given to maximize its effect. In the next series of experiments, we
sought to establish the time course of the injury-induced proliferative response in SCI and
relate this to gliotic scar formation with the use of flow cytometry. In order to ascertain
the validity of using flow cytometry to count cells of the central nervous system (CNS), a
preliminary study using mixed glial cultures was first completed (Figure 5.3). When it
was found that flow cytometry can reliably count vimentin+ and GFAP+ cells, the
chronicling of the injury-induced proliferative response with in vivo experiments
proceeded (Figure 5.4). For reactive astrocytes, which are labeled with vimentin, the
peak period of proliferation lasts from day 2 to 5 post-injury (Figure 5.4G). We then
found that a single targeted 15-Gy exposure of irradiation to the lesion site at day 2 postinjury reduced the proliferating cell population by over 50 % (Figure 5.4H).
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Discussion
We hypothesized that irradiation treatment, when targeted to the site of spinal
cord trauma, may reduce the injury-induced proliferative cell population. As this
population contributes significantly to the formation of the gliotic scar, the reduction of
this cell population would reduce scar formation and create a more favorable
environment for axonal regeneration. However, since the gliotic scar contributes a
number of important benefits, we merely want to “punch a few holes” such that
regrowing axons can penetrate the physical barrier aspect of the scar while scar integrity
can be preserved to prevent the spread of cellular destruction. To optimize the process,
we completed several preliminary experiments in order to determine the lowest dose that
can be used to maximally attenuate the injury-induced proliferative response as well as
the best timeframe for administration.
In this study, though we showed how irradiation can attenuate the injury-induced
proliferative response post-SCI, we never proceeded to determine the extent to which
irradiation can improve functional outcome. In the past several years, there has been
increasingly strong evidence that the reactive astrogliotic process and subsequent gliotic
scarring play an imperative role in neuroprotection during the early acute phase of injury.
As discussed previously, it has been known for some time that the scar possesses a
beneficial role, especially in the establishment of a new glia limitans around the lesion.
However, mounting evidence as to the scar being inhibitory to regeneration has led to the
common general perception that it is something that should aggressively be removed or at
least reduced in size even though earlier evidence has shown scar ablation to drastically
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increase lesion volume and promote neuronal and oligodendrocyte cell death (Bush et al.,
1999; Fauklner et al., 2004). In view of the many recent studies that show how the gliotic
scar goes beyond just isolating the lesion post-injury, specifically the roles of sealing the
blood-brain barrier, preventing overwhelming inflammatory infiltration, supplying
various growth factors, and even promoting axonal sprouting (Okada et al., 2006;
Renault-Mihara et al. 2008; Rolls et al., 2009), the overall perception of the scar being
unfavorable post-SCI is slowly changing.
Though it is still true that the scar represents a barrier to regeneration, both
physically and biochemically, this recent paradigm shift of regarding gliotic scar
formation as almost necessary during the immediate and acute phases of injury leads us
to reconsider the advantages of attenuating the injury-induced cellular proliferation so
early on post-SCI. However, once the SCI lesion is stabilized and the process of gliosis
occurred to such an extent that the scar causes more harm than benefits, we believe the
continuing injury-induced proliferation, despite having peaked earlier, can still be
attenuated by way of irradiation to facilitate a more efficient penetration of regrowing
axons into and beyond the gliotic scar.
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Figure 5.1. (A) The MASCIS Impactor, developed in 1991 by Drs. John Gruner, Carl
Mason, and Wise Young, is a device used to deliver reproducible spinal cord contusions
in rats. A 10-g rod can be dropped onto an exposed rodent spinal cord from a distance of
12.5, 25, or 50 mm, which equate approximately to a mild, moderate, or severe contusion
SCI respectively. (B) The white spinal cord is exposed after completing a laminectomy
at the vertebral level T8. (C) The spinal frame holds the animal via two spinous
processes adjacent to the laminectomy so that the exposed segment of the cord is aligned
directly beneath the rod.
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Figure 5.2. A single dose of irradiation can drastically reduce the number of
proliferating cells in the injured cortex. (A) Sections immunolabeled with BrdU (green)
and GFAP (red) showing the injury-induced proliferative response 4 d following a
cortical stab wound (arrow). (B) The reduction of this response as a result of a single
dose of irradiation directed locally at the wound site 2 d post-injury.
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Figure 5.3. Flow cytometry can reliably count vimentin+ and GFAP+ cells. Unpurified
glial cultures were trypsinized, resuspended, fixed, and permeabilized. Cells were first
labeled with 7-AAD to identify cells from debris (A) and subsequently labeled with
fluorochrome-conjugated antibodies for BrdU, vimentin, and GFAP. Negative control
antibodies were used to facilitate the setting of quadrant gates for the BrdU-vimentin
analysis (B) and BrdU-GFAP analysis (C). Flow cytometric counts (F and G) were
comparable to that of actual counts done on immunolabeled cultures (D and E). A
similar study was also completed using glioblastoma cells and cell counts using all three
markers were equally comparable between flow cytometric and manual
immunocytochemical counts (Data not shown).
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Figure 5.4. Spinal cords of rats were percussively injured by a 10-g weight drop from 25
mm. To obtain the flow cytometric dataset displayed here, on day 4 post-injury, animals
were given two doses of BrdU. On day 14 post-injury, the 5-mm spinal cord segments
containing the lesion epicenter from three experimental groups of rat (sham, injured, and
injured with irradiation) were mechanically dissociated into a cell suspension, fixed, and
permeabilized. Cells were first labeled with 7-AAD to identify cells from debris (A) and
subsequently labeled with fluorochrome-conjugated antibodies for BrdU and vimentin.
To facilitate the setting of quadrant gates for the analysis, cells from the spinal cord of a
non-BrdU treated sham animal were used (B). In sham animals, very little proliferation
was seen as shown by BrdU immunohistochemistry (C) and as indicated by low flow
cytometric counts of BrdU+ events in the top two quadrants (1.0% + 2.1%) (E). In
contrast, in injured animals, there is a massive increase of cell proliferation as shown by
BrdU immunohistochemistry (D) and flow cytometry (4.6% + 19.0%) (F). Moreover, a
large number of these proliferating cells are vimentin+ (19.0%). The above described
process was repeated with BrdU being administered at different time points and a graph
depicting the chronicling of the proliferative response of vimentin- and GFAP+ cells was
generated (G). A single dose of irradiation administered at the beginning of the peak
period of proliferation (day 2 post-injury) was able to attenuate the injury-induced
proliferative response as indicated by flow cytometry (H). Scale Bar (C) = 1 mm.
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Chapter 6
Concluding Statement

Traumatic spinal cord injury (SCI) is a debilitating, costly, and emotionally
devastating condition that is characterized by marked neuropathology and limited
recovery of function. While the initial insult rapidly disrupts neural tracts and kills cells,
an insidious, complex secondary cascade of cellular and biochemical events soon
follows. Glial cells such as astrocytes react to the injury by proliferating and
hypertrophying, which results in the development of a gliotic scar that partitions the
lesion epicenter from viable tissue. Although this process aids to prevent the spread of
uncontrolled tissue damage, the scar nevertheless acts as a physical barrier to axonal
regeneration. Furthermore, the scar and the cells within are a major source of axon
growth-inhibitory molecules such as chondroitin sulfate proteoglycans (CSPG) and thus
concomitantly acts as a biochemical barrier. Concurrently, inflammatory cells infiltrate
the cord parenchyma and through immunologic activation, possess the capacity to
exacerbate damage by propelling viable cells into apoptosis. Additionally, the severing
of axons results in the interference of neurotrophic support, making neuronal survival
precarious. Finally, the pathology culminates in the formation of a fluid-filled cyst,
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which puts in place yet another insuperable hurdle for regrowing axons to overcome.
Collectively, these pathological processes perhaps partially explain the lack of effective
central nervous system (CNS) recovery seen following SCI.
Up until the recent decades, there was little hope for the successful treatment of
SCI. But despite our incomplete understanding of the mechanisms that control these
pathological processes, we now know that they are amenable to therapeutic interventions
that may promote neuroplasticity and the regeneration of axons, leading to improved
functional outcomes. Moreover, it has been demonstrated numerous times that adult
CNS neurons retains the ability of regrowing functional axons (Richardson et al., 1980;
von Meyenburg et al., 1998; Chuckowree et al., 2004). In view of this, when provided
with a permissive microenvironment, the notion of severed axons regenerating is indeed a
very valid possibility.
In this dissertation, we introduced a few of our own strategies to overcome the
aforementioned therapeutic challenges post-SCI. We employed electrospinning to
generate a biocompatible matrix implant that can bridge and direct axonal elongation
across the fluid-filled cyst. Given the complex array and scope of pathological sequelae
post-SCI, it is generally recognized that successful treatment requires a multifaceted
approach. In view of this, we presented novel approaches by which successful tried and
true therapeutic strategies are combined. To facilitate the delayed but necessary longterm release of an enzyme capable of neutralizing the axon growth-inhibitory activity of
CSPGs, chondroitinase ABC was incorporated directly into our electrospun matrices and
tested. And to ensure an immediate replacement source of neurotrophic support during
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the acute phase of the injury, we tested the use of an alginate microsphere vehicle that
can also be incorporated into our electrospun matrices to deliver growth factors and other
potential neuroprotective and growth-promoting agents. To address the injury-induced
proliferative response, which represents an on-ramp off-ramp obstacle that prevents
axonal regeneration onto our matrix implant, we showed how X-irradiation can moderate
the the injury-induced proliferative glial response so as to facilitate a more efficient
penetration of regrowing axons into and beyond the gliotic scar. And finally, FTY720
was utilized as a pharmacologic intervention to prevent lymphocytic egress from
lymphoid tissues and reducing the infiltration of lymphocytes into the cord parenchyma
post-SCI, which resulted in improved hindlimb motor recovery.
Although many of the ideas presented have been assessed in animal studies and
these experiments have produced results that demonstrated potential and optimism, these
strategies may not translate easily into human SCIs without additional effort. As
mentioned previously, the presentation of cysts formed post-SCI is highly variable in
both its time of emergence and spatial dimensions. While the timeframes of the many
cellular and molecular events have been chronicled in the rodent models of SCI,
researchers have only a rudimentary understanding of such details in human cases of
SCIs due to the sparse availability of study specimens. A determination of the
appropriate time to implant our or any other experimental scaffold bridges post-SCI in
humans will be required to optimize regeneration. Additionally, while cavities formed
post-injury in human SCIs are inherently larger than those of rat SCIs, fitting, aligning,
and implanting our bridging matrices into these narrow cysts may not be trivial.
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Although extreme, some have suggested transecting and removing the damaged cord
segment in contusion SCI patients that have absolute complete cord injuries and replacing
the segment with a bridge in a process similar to our animal trials. There is some merit
with this radical procedure since much of the inhibition and barrier effects are removed
instantly. Additionally, a laceration of the cord, such as this method, has been shown to
produce little gliotic scarring, which would enable the cord stubs to act as a more
permissive on-ramp off-ramp zone after bridge implantation. Naturally, this approach
would not be a therapeutic solution for incomplete SCI patients with cords that have
some level of white matter sparing.
Another notion of interest is the use of our electrospun matrix implants during the
chronic phase of human SCI, which generally begins six months to a year after the initial
traumatic insult. Although research targeting the chronic phase of the injury is sorely
lacking, what is known is rather discouraging. In a longstanding injury, the diminished
regenerative capacity of the neurons and the increasing rigid scar barriers at and beyond
the lesion site make functional recovery even more of a challenge. Potential therapies
that have shown promise when applied acutely, have almost all shown to fail when
employed to injuries older than four weeks in animal models of SCI (Houle and Tessler,
2003). At this point with our current understanding, it is most likely that the best
therapeutic time window will reside during the early stages of the injury’s pathological
progression.
Table 6.1 displays a general but almost exhaustive list of therapeutic obstacles
arranged by the timeframes in which they occur after traumatic SCI. Each of these
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phases presents a number of known therapeutic aims. A combination of treatments that
target in a serial fashion the listed objectives during the appropriate timeframe would
probably give SCI patients the best chance at regenerating axotomized neurons and
recovering lost physiological functions. Despite this well-recognized point of view, very
few combinatory strategies have been documented in the literature. This is not surprising
given the difficulty of the problem and the enormous amount of resources required to
carry out experiments based on a combinatory approach. Nevertheless, in the short span
of four years, we came up with a few novel ideas, tested them experimentally, and have
started to combine some of these potential treatment strategies. As discussed in Chapter
5, we have now obtained some promising preliminary results from our matrix implant
trials in animals. Though more in vivo runs are required to show conclusively that our
electrospun matrix is able to bring about functional improvements post-SCI, we plan to
combine our other treatment approaches as well as other outside strategies that have been
proven to be successful.
Collectively, the ideas presented in this manuscript and the results from
experimentally testing these ideas represent a new body of knowledge that, if perhaps
only incrementally, advance the pathological understanding as well as the treatment of
traumatic SCI.
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SCI phases, timeframe of phases, key events, and therapeutic aims within each phase
Phases
Approximate
Timeframe
in
Human
Injuries
Events
and
Potential
Therapeutic
Obstacles

Immediate Phase

Acute Phase

Subacute Phase

Intermediate Phase

Chronic Phase

Immediately to Hours
after injury

Hours to days
after injury

Days to weeks
after injury

Weeks to months
after injury

Months to years
after injury







Primary
mechanical
insult
Severing
of axons
Hyperemia
Blood
vessel damage
and hemorrhage
Microglial
activation




Edema
Ischemia
and hypoxia
Hemorrha
gic necrosis
Excitotoxi
city
Bloodspinal cord
barrier
degradation
Demyelina
tion
Inflammat
ory infiltration



Reactive
astrogliosis



Gliotic
scarring

Cyst
formation



Wallerian
degeneration

Neuroprot
ection and
promotion of
neuronal
survival

Immune
modulation



Modulatio
n of injuryinduced
proliferation
Promotion
of regeneration
Remyelina
tion
Neutralizat
ion of myelin
debris and
proteins
Neutralizat
ion of
proteoglycans





Physical
Rehabilitation








Major
Therapeutic
Goals
Within
Phase
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Cyst
bridging
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Table 6.1. The aftermath of SCI is divided into five phases: the immediate phase, acute
phase, subacute phase, intermediate phase, and chronic phase.
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Appendix
FTY720 Reduces Inflammation and Promotes Functional
Recovery after Spinal Cord Injury

Introduction
The pathophysiology of spinal cord injury (SCI) has classically been partitioned
into primary and secondary injury processes. As described previously, after the initial
primary injury, secondary injury encompasses an insidious cascade of cellular and
biochemical events, the magnitude of which is rivaled only by its complexity. Within
this milieu of events, inflammation has been identified as an important component of
secondary injury and numerous cell populations have been implicated as mediators of
inflammation. Among these cells, lymphocytes have generated interest for their key
involvement in the concept of trauma induced autoimmunity (Popovich et al., 1996;
Gonzalez et al., 2003; Ankeny et al., 2006). This concept is based on the hypothesis that
traumatic injury results in the release of neural self-antigens and subsequent immunologic
activation. In support of this possibility, injection into naïve animals of T cells isolated
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from rats subjected to SCI resulted in central nervous system (CNS) tissue injury and
neurological deficit (Popovich et al., 1996).
Many of these studies in SCI and autoimmunity have drawn on parallels from our
current knowledge of multiple sclerosis (MS) and the animal model experimental
autoimmune encephalomyelitis (EAE). In both of these processes, T cells are known to
infiltrate the CNS, resulting in demyelination and neurologic dysfunction. Targeted
therapies for MS have therefore focused on immunomodulation, specifically in the T cell
population.
Fingolimod administration is one of the newest immunomodulatory therapies for
MS and is currently undergoing phase III clinical trials as a monotherapy. Fingolimod,
commonly known as FTY720, is a chemical derivative of the fungal metabolite myriocin
and in its phosphorylated form, acts as a spingosine-1-phosphate (S1P) mimetic and
agonist of the S1P receptor (Brinkmann et al., 2002). Several groups have shown that
administration of FTY720 results in a significant reduction in peripheral lymphocyte
counts (Chiba et al., 1998; Brinkmann et al., 2000; Pinschewer et al., 2000). It has been
postulated that FTY720 induces this lymphopenia by preventing lymphocyte egress from
peripheral lymphoid organs. Once FTY720 binds to the S1P receptor, internalization and
subsequent degradation of the receptor occurs (Matloubian et al., 2004). This
degradation thereby eliminates the necessary S1P signal for lymphocyte egress and
prevents recirculation into the CNS (Brinkmann et al., 2002; Mandala et. al., 2002;
Matloubian et al., 2004).
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Independent of this ability to prevent lymphocyte migration, FTY720 has also
been shown to have other cytoprotective capabilities. Studies have shown that FTY720
can prevent apoptosis in neural cells and act on endothelial cells to preserve vascular
integrity (Fujino et al., 2003; Brinkmann et al., 2004; Coelho et al., 2007). The exact
mechanisms of these effects are still under investigation.
In the series of experiments presented in this chapter, we examined the efficacy of
FTY720 in a moderate to severe contusion model of SCI. We hypothesized that
administration of FTY720 would reduce infiltration of T cells to the spinal cord lesion
site and enhance functional recovery after SCI. Our results indeed demonstrate the
efficacy of FTY720 in a model of CNS trauma and show that administration enhances
tissue preservation and functional outcome after SCI.

Materials and Methods
Animal Model and Surgical Procedures
Adult Long Evans Hooded rats aged approximately 70 days were used for the
contusion SCI protocols. The surgical procedure employed in this study was identical to
that used in the previously discussed study of Chapter 5 and details of the method can be
found in that chapter.
Immediately after injury, animals were randomized to receive an intraperitoneal
injection of FTY720 (1 mg/kg body weight) (Cayman Chemical, Ann Arbor, MI)
solubilized in 0.1% dimethyl sulfoxide (DMSO), vehicle (0.1% DMSO), or no injection
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(injury only). Animals were then allowed to recover in a separate area with a warming
blanket.
All animals received prophylactic gentamicin (5 mg/kg body weight) before
surgery and daily thereafter for 7 d. Manual bladder expression was performed three
times daily for the first week after surgery and two times daily thereafter until
spontaneous micturation was reestablished. Urine volumes were recorded at each
collection and spontaneous micturation was defined as established when daily volumes
collected were less than 2 ml total for 3 consecutive days. Expressed urine was also
monitored for evidence of urinary tract infection (UTI) by the presence of elevated urine
pH or leukocytes and treated with a 5-d course of gentamicin if diagnosed.

Flow Cytometry
For flow cytometry, injured animals received daily intraperitoneal injections of
either FTY720 (n = 5) or vehicle (n = 5) until sacrificed. On the first, fourth, and seventh
days post-injury, animals were sacrificed with a lethal dose of pentobarbital and perfused
transcardially with phosphate buffered saline (PBS). A 1-cm section of the cord centered
to the impact site as well as the spleen was then harvested. Both the cord and spleen
tissue were individually dissociated by passage through a 70-µm filter and washed twice
with PBS. Erythrocytes were lysed with tris-buffered ammonium chloride. Leukocytes
were identified as round, phase-bright entities with a diameter of approximately 10 µm
that excluded trypan blue and were enumerated on a hemocytometer. Antibodies used for
phenotypic analysis were anti-CD3, -CD4, -CD8α, -CD11b, and -His48 and were
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biotinylated or conjugated to R-phycoerythrin or fluorescein isothiocyanate (BD
Biosciences). Streptavidin conjugated to allophycocyanin was used for the detection of
biotinylated antibodies. Approximately 1 × 106 cells were stained with 0.5 µg of each
monoclonal antibody as previously described (Graf et al., 2001). Cells were then fixed
with Cytofix (BD Biosciences), permeablized with Cytoperm (BD Biosciences), washed
with PBS, and stained with the DNA-specific dye 7-aminoactinomycin (7-AAD) at a
concentration of 10 µg/ml. Three-color fluorometric analysis was performed using a
FACSCanto flow cytometer (BD Biosciences). Cells were identified as 7-AAD+ events
on a FL3 verses side scatter histogram as described by Lipton et al. (2005) and 10,000 7AAD+ events were analyzed. T cell subsets were identified as CD3+/CD4+ or
CD3+/CD8+ double-positive cells. Monocytes and granulocytes were identified as
CD11b+ and His48+ cells, respectively.

Behavioral Outcome Assessment
All animals were gentled in an open field twice a day for 7 consecutive days prior
to injury. Animals randomized to the treated group (n = 11) received daily
intraperitoneal injections of FTY720 for 4 weeks. Vehicle group animals (n = 10)
received daily intraperitoneal injections of 0.1% DMSO for the same time period. The
injury only group (n = 9) received no injections. Laminectomies were performed on
sham animals (n = 2) but no cord injuries were performed and no injections administered.
At day 2 and 7 post-injury and once weekly thereafter for a total of 6 weeks, rats were
placed in the open field and observed for 4 min (Figure A.1A). Two researchers blinded
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to treatment groups observed the animals in open field testing. Gross locomotor recovery
after SCI was assessed using the Basso-Beattie-Bresnahan (BBB) locomotor rating scale
as shown in Table 3.1 (Basso et al., 1995). Observations for each hind limb were scored
and averaged to provide a single score for each animal per session. All data were
collected within the 4 min period. Once a plateau in locomotor recovery was evident
(generally after day 28 post-injury), a frequency analysis of plantar stepping and
coordination was performed across all groups.
All animals were also tested on the inclined plane task (Figure A.1B). This task
evaluates the animal’s ability to maintain a horizontal body position on an inclined board.
The angle of the board is incrementally raised until the animal is no longer able to
maintain the horizontal position. Performance on the inclined plane correlates with the
integrity of the rubrospinal tract (as well as other non-pyramidal pathways) after SCI.
During testing, animals were placed in the right and left side up positions. The maximum
angle at which the animal was able to maintain position on the board for 10 s was
recorded for each side. Data were recorded as the average of the two sides to obtain a
single score for each animal per session.

Analysis of Myelin Sparing
At week 6 post-injury, animals were sacrificed with a lethal dose of pentobarbital
and perfused transcardially with PBS followed by 4% paraformaldehyde. Spinal cords
were harvested and postfixed for 2 h in the same fixative before being immersed in PBS
overnight. The fixed cords were then cryoprotected in 30% sucrose for 48 h. FTY720-
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treated (n = 9) and vehicle (n = 8) cords were blocked and embedded together in optimal
cutting temperature compound and sectioned at a thickness of 20 μm. A complete series
of axial sections spanning the injury site was collected and stained with eriochrome
cyanine (EC) to assess for myelin sparing. Also, axial sections peripheral to the injury
epicenter were collected at 0.5-mm intervals and stained with EC. For each spinal cord,
the lesion epicenter was qualitatively defined by a blinded researcher as the section
containing the least amount of intact tissue. This section and sections located 100 μm
rostral and caudal were chosen to quantify the area of spared myelin at the epicenter.
Light microscopy at 25 × magnification was used to visualize the sections and images
were captured with an Olympus DP12 camera. These images were then imported into
ImageJ, an open architecture image processing program developed at the National
Institutes of Health, and white matter sparing analysis was performed by a blinded
observer. Percent myelin spared was calculated by manually outlining the spared white
matter regions which then generated an area as denoted by the number of pixels. This
area was then divided by the total cross-sectional area of the axial section. The average
of the three sections was used to denote the percent myelin spared at the injury epicenter.
In the same fashion as described above, sections rostral and caudal to the epicenter at 0.5mm intervals were analyzed for white matter sparing.

Statistical Analysis
The data presented here in this chapter is reported as means ± standard error of
the mean. All statistical analyses were performed using the statistical software package
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SPSS. Open field, inclined plane, and urine volumes data were analyzed by repeated
measures two-way analysis of variance (ANOVA) with post hoc pairwise comparison
test. Days to spontaneous voiding data was analyzed by one-way ANOVA with post hoc
Tukey analysis. The Fisher’s exact test was used for hematuria incidence and locomotor
frequency analysis. Flow cytometry and myelin sparing analysis data were compared
using Student’s t-test. Differences with a p value less than 0.05 were considered
statistically significant.

Results
FTY720 reduces T cell infiltration to the spinal cord lesion site after injury.
FTY720 is known to be a potent immunomodulator and numerous reports have
shown that administration reduces peripheral lymphocyte circulation (Chiba et al., 1998;
Brinkmann et al., 2000; Pinschewer et al., 2000). In order to establish the efficacy of
FTY720 treatment in a model of SCI, we quantified inflammatory cell infiltration into
injured spinal cord using flow cytometry. Data from this analysis showed that FTY720
administration significantly reduced the infiltration of CD4+ T helper cells to the spinal
cord lesion site as compared to vehicle administration at day 4 post-injury (7.56 ± 0.25
vs. 3.80 ± 0.5, p < 0.001) (Figure A.2D). This response was similar to the reduction seen
in the CD8+ cytotoxic T cell population (7.80 ± 1.01 vs. 3.68 ± 1.31, p = 0.008). At day
7 post-injury, a similar reduction was seen in the CD4+ T helper cells (10.01 ± 1.40 vs.
6.40 ± 0.72, p = 0.048) and in the CD8+ cytotoxic T cell population (8.51 ± 0.51 vs. 6.01
± 0.40, p = 0.009). However, there was no difference noted in either cell population at
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day 1 post-injury. For all time points, no statistical difference was noted between vehicle
and FTY720 administration in the spleen tissue.
In order to evaluate for other inflammatory cell populations infiltrating the spinal
cord after injury, antibody labeling for His48 (granulocytes) and CD11b (monocytes) was
performed (data not shown). A slight trend towards reduction was observed with
FTY720 administration in the His48+ (24 ± 2.4 vs. 20.2 ± 1.9, p = 0.29) and the CD11b+
cell populations (40.3 ± 1.47 vs. 32.8 ± 7.5, p = 0.38). However neither of these
differences was statistically significant, suggesting that FTY720 specifically inhibits T
cell infiltration.

FTY720 promotes hind limb recovery after spinal cord injury.
Once we established the efficacy of FTY720 in a model of SCI, our next step was
to determine the extent to which administration would impact functional recovery. Hind
limb function was therefore evaluated for 6 weeks after injury using the open field and
inclined plane tests. During the acute and intermediate recovery stages, no differences in
BBB locomotor scores were noted among groups (Figure A.3A). However, by day 21
post-injury the mean BBB score in the FTY720-treated animals surpassed those of the
vehicle animals by 1.4 (11.5 vs. 10.1, p = 0.02). Moreover, this difference was sustained
throughout the remainder of the analysis even after drug treatment was discontinued at
day 28 post-injury. By the end of the analysis, the mean difference between treated and
vehicle groups was 1.5 (12.5 vs. 11.0, p = 0.001). No differences were noted between
vehicle and injury only groups at any time point.

125

A frequency analysis of the open field data is shown in Table 3.2 and reflects
differences in locomotor milestones between the groups once recovery reached a plateau.
For each time point analyzed, a significantly greater proportion of animals were
consistently plantar stepping (BBB ≥ 11) or stepping with occasional coordination (BBB
≥ 12) in the FTY720-treated group as compared to vehicle and injury only groups. By
day 42 post-injury, all animals in the FTY720-treated group were consistently plantar
stepping and 81.8% exhibited at least occasional coordination. In contrast, only 80% of
animals in the vehicle group exhibited consistent plantar stepping and only 20% were at
least occasionally coordinated.
Performance on the inclined plane mirrored open field testing performance with
the exception that differences were noted at earlier times along the study (Figure A.3B).
By day 14 post-injury, the mean difference between treated and vehicle groups was 6.5°
(35.5 vs. 29, p < 0.0001). Average angles were consistently higher in the treated group
for the duration of the study and at day 42 post-injury the mean difference between
treated and vehicle groups was 8.6° (43.9 vs. 35.3, p < 0.0001)
For both the open field and inclined plane tests, no significant difference in scores
was detectable at any time point between vehicle and injury only control groups. Linear
regression analysis revealed a very strong correlation (r = 0.87) between the BBB and
inclined plane scores for all time points (Figure A.3C).
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FTY720 improves bladder function after spinal cord injury.
A well-known consequence of SCI in both animals and humans is bladder
dysfunction. Using an animal model of SCI, Wrathall et al. (2006) showed that injury
severity could be directly correlated with degree of bladder dysfunction, which was
reflected in the volume of urine collected during manual expression. We therefore sought
to utilize bladder function as another measure of functional recovery. Figure A.4A shows
that all animals had impaired bladder function immediately after SCI. However, animals
in the treated group had significantly lower mean urine volumes expressed as compared
to vehicle and injury only groups (n = 10 for each group, p < 0.0001). Post hoc analysis
also revealed no statistical difference between vehicle and injury only groups in terms of
daily urine volumes collected.
For all animals, daily bladder expressions were performed until total daily volume
collected was less than 2 ml for 3 consecutive days, indicating return of spontaneous
bladder function. Inter-group comparison of the number of days required to reach this
milestone revealed that animals in the treated group required fewer days as compared to
vehicle and injury only groups (Figure A.4B) (6.2 ± 0.4 vs. 10.3 ± 0.6 and 9.8 ± 0.74, p <
0.0001). No statistical difference was noted between vehicle and injury only groups.
For each urine collection, urine color was recorded. Retrospective analysis of the
incidence of gross hematuria revealed that FTY720 treatment significantly reduced the
incidence of gross hematuria as compared to vehicle and injury only groups (Figure
A.4C) (45.5% vs. 90% and 100%, p = 0.002). No difference was noted when comparing
vehicle and injury only groups with each other.
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FTY720 and Body Weight
One important aspect of assessing the utility of an immunosuppressant drug is
determining whether the drug has an unacceptable level of toxicity. Many
immunomodulators, although useful in their ability to reduce inflammation, are limited
by their toxicity profile. Animal body weight was used as an indicator of general toxicity
and monitored throughout the course of the study. Decreases in body weight can indicate
failure to thrive which would then imply drug toxicity. However, no significant
differences in percent change in body weight were noted among the three treatment
groups studied (Figure A.5).

Locomotor recovery correlates with myelin sparing.
In order to correlate locomotor recovery results with histological findings, we
performed myelin sparing analysis of the lesion epicenter. Animals were sacrificed at the
end of the final open field testing and spinal cords were harvested for EC staining. Due
to the lack of differences detected in behavioral outcome between the vehicle and injury
only groups, we confined our analysis to the treated (n = 9) and vehicle groups (n = 8) for
comparison. The data showed that FTY720 treatment resulted in a significant increase in
the percentage of myelin spared (Figure A.6C) (28.5 ±1.6 vs. 20.8 ± 1.7, p = 0.004). By
linear regression analysis, final BBB scores also had a very strong correlation with
percentage of myelin spared at the epicenter (Figure A.6D, r = 0.75).
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Discussion
The data presented in this study demonstrate that FTY720 administered after SCI
dramatically reduces T cell infiltration into the spinal cord. Furthermore, the results of
behavioral outcome analyses revealed that treatment with FTY720 was effective in
enhancing hind limb and bladder recovery. Interestingly, the effect of FTY720 on hind
limb function was evident during the chronic phase of recovery in contrast to its effect on
bladder function which was noted during the acute recovery phase. Results from
morphometric analysis also provided support for the neuroprotective capacity of FTY720
and revealed that white matter preservation is enhanced with treatment.
Our initial step in establishing the efficacy of FTY720 in SCI was to determine
whether treatment would affect lymphocyte infiltration into the spinal cord after injury.
Analysis by flow cytometry revealed that treatment with FTY720 after SCI significantly
reduced T cell infiltration into the spinal cord whereas granulocyte and monocyte
populations were relatively unaltered. These data are in agreement with previously
reported studies that showed that FTY720 had differential effects on CD4+ and CD8+ T
cells and minimal effects on peripheral blood counts of granulocytes and monocytes
(Quesniaux et al., 1999; Budde et al., 2003; Kahan et al., 2003; Bohler et al., 2004). The
degree of lymphocyte reduction has been shown to be dose-dependent but previously
reported reduction ranges of 30 to 70% (Quesniaux et al., 1999; Bohler et al., 2004) are in
good agreement with the data reported in this study of 50 to 59%.
Our flow cytometry results clearly demonstrated the efficacy of FTY720 as an
immunomodulator in post-SCI inflammatory response. However, the question remained
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as to whether this would have a beneficial or detrimental effect on functional recovery.
Although inflammation is a well-established sequela of CNS trauma, its role in recovery
has been somewhat controversial. Both beneficial and detrimental effects have been
associated with the inflammatory process. Through the release of cytokines and other
factors, inflammatory cell populations such as neutrophils and macrophages have long
been associated with CNS toxicity (Chao et al., 1992; Bao et al., 2002; Shamash et al.,
2002; Donnelly et al., 2008). Various groups have further demonstrated that attenuation
of these inflammatory mediators is beneficial and promotes neurologic recovery (Giulian
et al., 1990; Blight, 1994; Popovich et al., 1999; Gris et al., 2004; Pannu et al., 2005;
Beril et al., 2007). However, it has also been suggested that inflammation may play a
dual role in neural recovery and may have significant beneficial aspects. As surveyors of
the CNS, microglia have been hypothesized to have a clearing mechanism after spinal
cord injury, eliminating debris and reducing the presence of any factors that might play
an inhibitory role in CNS repair. These cells are known for their cytotoxic capabilities
but they have also been shown to secrete trophic factors for both neurons and glia (Banati
and Graeber, 1994; Kreutzberg, 1996). There is also evidence that macrophages may
have a neuroprotective role in the CNS (Rimaniol et al., 2000; Yin et al., 2006).
The concept of protective autoimmunity has been championed by some with the
implication that enhancement rather than attenuation of the immune response is necessary
to promote CNS recovery (Schwartz and Kipnis, 2001, 2002; Yoles et al., 2001).
Experimental data revealed that augmentation of the immune response via passive or
active immunization with myelin basic protein limited secondary degeneration and
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improved functional recovery after SCI (Hauben et al., 2000, 2001). As a result, efforts
have been made to design vaccines for various neurodegenerative diseases as well as for
CNS trauma (Schwartz, 2001). However, the concept of protective autoimmunity also
runs counter to the classic concept of T cells as pathologic entities. Using T cells isolated
from spinal injured rats, Popovich et al. (1996) demonstrated that injection into naïve rats
resulted in neurological deficit and pathology reminiscent of EAE. Subsequent studies
using transgenic mice and athymic nude rats also support the traditional view of the T
cell as a pathogenic entity (Jones et al., 2002; Potas et al., 2006). Interestingly,
independent efforts to replicate the original experimental vaccine protocols of Hauben et
al. (2000, 2001) failed to demonstrate any benefit and in fact revealed that functional
recovery was impaired with vaccination (Jones et al., 2004). This has raised some
questions regarding the safety and utility of intentionally activating CNS-reactive T cells
(Popovich and Jones, 2003; Jones et al., 2004).
It is clear therefore that the only conclusion that can be made regarding the
inflammatory response is that it is quite complex and these studies only bolster the notion
that the role of inflammation cannot be succinctly distilled as either beneficial or
detrimental. In this present study we showed that administration of FTY720 dramatically
reduced T cell infiltration into the spinal cord lesion site and enhanced locomotor
recovery as well as tissue preservation after SCI. Although the locomotor enhancement
observed in the open field and inclined plane tests was modest, frequency analysis of the
open field data highlighted the differences between treatment groups. By the end of the
study, the vast majority of animals in the treated group exhibited at least occasional
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coordination whereas only a minority of animals in the vehicle group exhibited this
milestone. Previously reported studies by Gonzales et al. (2003) using a mouse spinal
hemisection model, also showed similar results after T cell infiltration was inhibited
using a neutralizing antibody to a T cell chemoattractant chemokine. Similarly, Ibarra et
al. (2003) showed that pharmacologic inhibition of T cell responses to spinal cord
antigens using cyclosporine improved functional recovery after SCI.
The results from this present study would then imply that the T cells attenuated by
FTY720 are deleterious in the process of recovery. Since FTY720 is not specific for all
inflammatory cell populations, it may be that treatment is inhibitory to pathologic
lymphocytic populations only and not to that subset which may have a beneficial role.
However, it is clear that the mechanism of action of FTY720 is not solely limited to
immunomodulation. In vitro studies have shown that FTY720 directly protects
oligodendrocyte progenitor cells (OPC) from apoptosis (Coelho et al., 2007). Studies
have also shown that FTY720 acts on endothelial cells and helps to preserve vascular
integrity and barrier function (Brinkmann et al., 2004). It is therefore possible that these
actions of FTY720 on vascular integrity and OPC cytoprotection could also play a role in
the observed effects of the drug treatment.
Another observation that was made in our present study was the effect of FTY720
on bladder function. Drug treatment dramatically reduced post-void residuals
immediately after SCI and reduced the number of days required to regain spontaneous
bladder function. This observation suggests a direct drug effect on bladder function
independent of spinal cord recovery. A link between FTY720 and bladder function is
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supported by in vitro studies on rabbit bladder smooth muscle which showed that
FTY720 can regulate detrusor muscle tone (Watterson et al., 2007). We also noted a
dramatic reduction in the incidence of hemorrhagic cystitis after SCI. This phenomenon
is known to occur after experimental SCI but the mechanism of this process has yet to be
well characterized. Experimental studies have linked inflammatory changes in the spinal
cord with disruption of bladder epithelium and hemorrhage (Doggweiler et al., 1998;
Apodaca et al., 2003). Interestingly, studies have shown that FTY720 can act on
endothelial cells and help to preserve vascular integrity and barrier function (Brinkmann
et al., 2004). Thus, it is possible that this preservation of vascular integrity is responsible
for the reduced incidence of hemorrhagic cystitis observed in this study.
The effect of FTY720 on bladder function, although dramatic, represented a
possible confounder and limitation of this study. Overall, fewer UTIs were diagnosed in
the treated as compared to vehicle group which was reflected in the number of antibiotic
courses administered (6 vs. 14). This difference is hypothesized to be due to the robust
effect of treatment on bladder function. Animals that were able to void more efficiently
would retain less urine and therefore be at lower risk for UTI. Theoretically, this could
then confound our analysis since improved overall systemic status could result in
improved clinical scores in the open-field and inclined plane. However, there is a notable
disparity in the time frame in which the effects of FTY720 on locomotor scores and
bladder function are noted. If the above conjecture were true, then no disparity should be
present and locomotor improvement should be noted coincident with bladder function
improvement. Furthermore, there were no differences noted among treatment groups in

133

terms of body weight change, suggesting that overall systemic status was similar among
the groups. Finally, morphometric analysis also supports the neuroprotective capabilities
of FTY720 as improved bladder function would presumably not result in enhanced tissue
preservation in the spinal cord. Taken together this leads us to conclude that
administration of FTY720 enhances locomotor function independent of bladder function
and systemic status.
Our results suggest that treatment with FTY720 not only reduces the adaptive
immune response but also affords neuroprotection and enhances bladder function after
injury. Given the complexity of the posttraumatic inflammatory cascade, the results of
this study do not clarify the role of T cells in CNS recovery. However, these results do
reinforce the growing body of knowledge suggesting immunomoduation as a possible
therapeutic strategy in SCI.
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Figure A.1. (A) Weekly hind limb evaluations were completed by putting the animals
one at a time on an open field for 4 min. (B) In addition, assessment of functional
recovery included an inclined plane task.
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Figure A.2. FTY720 treatment reduces T cell infiltration into the spinal cord after
injury. After SCI, animals were injected with either vehicle or FTY720 for 1, 4, or 7 d.
A 1-cm segment of the cord centered on the impact site was then harvested from each
animal and prepared for flow cytometry. (A) Representative dot blots of the injury site of
a vehicle injected animal showing the 7-AAD+ population used for analysis (Gate P5).
(B) Representative dot blots of the injury site of a vehicle injected animal showing the
percentages of CD3+/CD4+ double-positive cells (Gate Q2) and of (C) CD3+/CD8+
double-positive cells (Gate Q2) within the 7-AAD+ gate. (D) A graphical summary of
the mean percentages of 7-AAD+ events that were CD3+/CD4+ and CD3+/CD8+ for
treated and vehicle animals at the various days post-injury (DPI). As shown by this flow
cytometric paradigm, FTY720 treatment reduces infiltration of both CD3+/CD4+ helper
and CD3+/CD8+ cytotoxic T-cell populations into the cord after SCI. *p < 0.05
compared with vehicle treated rats.
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Figure A.3. FTY720 promotes hind limb recovery after spinal cord injury. After SCI,
animals were randomly placed into one of three groups: injury only, vehicle, and
FTY720-treated. Functional assessments were performed weekly for 6 weeks. (A) Open
field assessment of hind limb locomotor function using the BBB scale. Starting at week
3, treated rats as a group performed significantly better than the control groups. No
significant differences were noted between vehicle and injury only groups at any time
point. (B) The inclined plane test. Treated animals outperformed members of the control
groups starting at week 2 and continued to do so for the duration of the study. (C) For all
time points, linear regression analysis revealed a very strong correlation between the
BBB and inclined plane scores (r = 0.87). *p < 0.05 compared with injury only and
vehicle treated rats.
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Figure A.4. FTY720 improves bladder function after spinal cord injury. Manual bladder
expression was performed three times daily for the first week after SCI and two times
daily thereafter until spontaneous micturation was reestablished. The residual urine
volumes of each animal were measured and recorded during each expression session to
provide an average daily urine volume for the first 2 weeks post-SCI. Furthermore,
during urine collection, gross hematuria was noted when observed. (A) The mean
residual urine volumes of treated rats were consistently and significantly lower than that
of the control groups. (B) Days required until spontaneous micturation was reestablished
as defined by an average daily volume of less than 2 ml for 3 consecutive days. Treated
animals did not require extended assistance in expelling urine and regained spontaneous
bladder function by day 6. Control animals did not reach such a milestone until day 10.
(C) FTY720 treatment significantly reduced the incidence of gross hematuria as
compared to control groups. *p < 0.05 compared with injury only and vehicle treated rats.
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Figure A.5. FTY720 treatment does not adversely affect body weight. Animal body
weights were measured and recorded throughout the duration of the behavioral outcome
study. Treatment with FTY720 did not affect body weight following SCI. (The horizontal
axis is presented on a logarithmic scale.)
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Figure A.6. Myelin sparing correlates with locomotor recovery. At the conclusion of
the behavioral outcome study (6 weeks post-SCI), animals were sacrificed and cords
were harvested and cryosectioned. Sections at the level of the SCI epicenter were stained
with EC to determine the extent of white matter sparing. (A) A representative EC-stained
cross-section at the level of the SCI epicenter from a vehicle animal. (B) A comparable
section from a FTY720-treated animal. (C) At the level of the SCI epicenter, FTY720
treatment resulted in a significant increase in the percentage of spared myelin as
compared to vehicle treatment. (D) A linear regression analysis of the final BBB
locomotor scores and spared myelin percentages at the epicenter exhibited a very strong
correlation (r = 0.75). (E) In addition to the myelin sparing analysis completed at the
injury epicenter, adjacent cord sections of every 0.5 mm up to 5 mm away from the
epicenter were similarly processed and analyzed. This analysis revealed that FTY720
treatment resulted in a significant increase in the percentage of spared myelin as
compared to vehicle treatment in adjacent areas of the injury epicenter, especially regions
caudal. (Negative distances on horizontal axis denote rostral direction whereas positive
denote caudal direction.) Scale bars (A and B) = 300 μm. *p < 0.05 compared with
vehicle treated rats.
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BBB Locomotor Rating Scale
0
No observable hind limb movement
1
Slight movement of one or two joints, usually the hip and/or knee
2
Extensive movement of one joint or extensive movement of one joint and slight movement of one other joint
3
Extensive movement of two joints
4
Slight movement of all three joints of the hind limb
5
Slight movement of two joints and extensive movement of the third
6
Extensive movement of two joints and slight movement of the third
7
Extensive movement of all three joints of the hind limb
8
Sweeping with no weight support or plantar placement of the paw with no weight support
9
Plantar placement of the paw with weight support in stance only (i.e., when stationary) or occasional,
frequent, or consistent weight supported dorsal stepping and no plantar stepping
10
Occasional weight supported plantar steps, no forelimb-hind limb coordination
11
Frequent to consistent weight supported plantar steps and no forelimb-hind limb coordination
12
Frequent to consistent weight supported plantar steps and occasional forelimb-hind limb coordination
13
Frequent to consistent weight supported plantar steps and frequent forelimb-hind limb coordination
14
Consistent weight supported plantar steps, consistent forelimb-hind limb coordination; and predominant paw
position during locomotion is rotated (internally or externally) when it makes initial contact with the surface
as well as just before it is lifted off at the end of stance or frequent plantar stepping, consistent forelimb-hind
limb coordination, and occasional dorsal stepping
15
Consistent plantar stepping and consistent forelimb-hind limb coordination; and no toe clearance or occasional
toe clearance during forward limb advancement; predominant paw position is parallel to the body at initial
contact
16
Consistent plantar stepping and consistent forelimb-hind limb coordination during gait; and toe clearance
occurs frequently during forward limb advancement; predominant paw position is parallel at initial contact
and rotated at lift off
17
Consistent plantar stepping and consistent forelimb-hind limb coordination during gait; and toe clearance
occurs frequently during forward limb advancement; predominant paw position is parallel at initial contact
and lift off
18
Consistent plantar stepping and consistent forelimb-hind limb coordination during gait; and toe clearance
occurs consistently during forward limb advancement; predominant paw position is parallel at initial contact
and rotated at lift off
19
Consistent plantar stepping and consistent forelimb-hind limb coordination during gait; and toe clearance
occurs consistently during forward limb advancement; predominant paw position is parallel at initial contact
and lift off; and tail is down part or all of the time
20
Consistent plantar stepping and consistent coordinated gait; consistent toe clearance; predominant paw
position is parallel at initial contact and lift off; tail consistently up; and trunk instability
21
Consistent plantar stepping and coordinated gait, consistent toe clearance, predominant paw position is
parallel throughout stance, consistent trunk stability, tail consistently up
Terms and Operational Definitions
Slight
partial joint movement through less than half the range of joint motion
Extensive
movement through more than half of the range of joint motion
Sweeping
rhythmic movement of hind limb in which all three joints are extended, then fully flex and extend again;
animal is usually lying on its side, the plantar surface of paw may or may not contact the ground; no weight
support across the hind limb is evident
No Weight Support
no contraction of the extensor muscles of the hind limb during plantar placement of the paw; or no elevation
of the hindquarter
Weight Support
contraction of the extensor muscles of the hind limb during plantar placement of the paw, or elevation of the
hindquarter
Plantar Stepping
paw is in plantar contact with weight support then the hind limb is advanced forward and plantar contact with
weight support is reestablished
Dorsal Stepping
weight is supported through the dorsal surface of the paw at some point in the step cycle
forelimb-hind limb
for every forelimb step an hind limb step is taken and the hind limbs alternate
Coordination
Occasional
less than or equal to half; <50%
Frequent
more than half but not always; 51-94%
Consistent
nearly always or always; 95-100%
Trunk Instability
lateral weight shifts that cause waddling from side to side or a partial collapse of the trunk
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Table A.1. The 21-point BBB locomotor scale used to rate functional recovery after
SCI. (Adapted from Basso et al., 1995)
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Percentage of Animals within Each Group Reaching Locomotor Milestones

Injury Only
Vehicle
FTY 720

Day 28 Post-Injury
PS
C
44.4% (4/9)
11.1% (1/9)
50% (5/10)
10% (1/10)
81.8% (9/11)*
63.6% (7/11)**

Day 35 Post-Injury
PS
C
55.6% (5/9)
11.1% (1/9)
70% (7/10)
20% (2/10)
100% (11/11)*
63.6% (7/11)**
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Day 42 Post-Injury
PS
C
66.7% (6/9)
33.3% (3/9)
80% (8/10)
20% (2/10)
100% (11/11)*
81.8% (9/11)**

Table A.2. Animals treated with FTY720 are more likely to reach locomotor milestones.
Frequency analysis of rats achieving consistent plantar stepping (PS) or occasional
coordination (C) between 4 and 6 weeks after injury. *p < 0.05 compared with injury
only and vehicle treated rats. **p < 0.005 compared with injury only and vehicle treated
rats.
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